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Ming Xie 
T FOLLICULAR REGULATORY CELLS PROMOTE THE GERMINAL CENTER 
REACTION AND ALLERGIC IGE RESPONSE WHILE REPRESSING 
ABNORMAL DIFFERENTIATION OF T FOLLICULAR HELPER CELLS 
 
Follicular T helper (TFH) and regulatory (TFR) cells are two key classes of 
CD4+ T cells found in germinal centers (GCs). The primary role of TFH cells is to 
help B cells form GCs to produce high-affinity antibodies during an infection while 
the role of TFR cells remains controversial. The transcriptional repressor Bcl6 is 
essential for the differentiation of TFH, TFR and GCB cells and understanding 
signaling pathways that induce Bcl6 and TFH cell differentiation are important. We 
observed that Bcl6 is highly up-regulated in activated CD4 T cells following glucose 
deprivation by a pathway involving the metabolic sensor AMP kinase. The 
transcription factor Blimp1 represses both TFH cell differentiation and Bcl6 
expression, and we show the major role of Blimp1 on TFH cell differentiation is to 
repress Bcl6 expression and not other genes in the TFH differentiation pathway. 
We also found Bcl6 positively regulates expression of the key TFH cell receptor 
PD-1 by inhibiting the repression of PD-1 by the transcription factor Tbet. The roles 
of TFH and TFR cells in controlling allergen-specific IgE were investigated using a 
peanut allergy model and strains of mice with alterations in the TFH and TFR 
pathways. We found TFR cells unexpectedly play an essential role in promoting 
and maintaining IgE production and anaphylaxis, as well as the GC reaction. 
Compared to control mice, TFR-deficient mice lacked circulating peanut-specific 
x 
IgE and anaphylactic responses were significantly weakened. Mechanistically, 
TFR cells require Blimp1 controlled IL-10 to promote GCB cell survival and IgE 
production. Blocking IL-10 signals mimicked the loss of IgE levels in TFR-deficient 
mice and rescued mice from anaphylaxis. Overall, these studies have defined 
novel roles of Bcl6, TFH and TFR cells in regulating antibody production by the 
GC reaction, and provide greater understanding of how allergic immune responses 
are controlled. 
Alexander L. Dent, Ph.D., Chair  
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INTRODUCTION   
Innate and adaptive immunity 
 The immune system defends the body against infectious pathogens and 
pathological tumor growth while uncontrolled immune responses could cause 
allergic or autoimmune diseases (1). Innate immunity and adaptive immunity are 
two major arms of the immune response that work cooperatively to generate 
effective protection against pathogens following infection or vaccination (1-3).  
 
Innate immunity 
 The first line of defense is the innate immunity with mechanisms in place 
ready for quick response to infections. Outer anatomical barriers like skin and 
mucosal surfaces are the first innate defense protecting us from infectious 
pathogens such as virus and bacteria (4, 5). Innate immune cells derived mostly 
from common myeloid progenitors form additional innate defenses in addition to 
the physical barriers mentioned above. The major types of innate immune cells 
include dendritic cells (DCs), macrophages, monocytes, mast cells, basophils, 
neutrophils, eosinophils and natural killer (NK) cells. Innate immune cells express 
pattern recognition receptors (PRRs) either on their surface or in the cytoplasm. 
One major type of PRR is toll-like receptors (TLRs) which recognize pathogen 
associated molecular patterns (PAMPs) such as double stranded RNA and 
mannans.  This recognition of PAMPs by PRRs leads to phagocytosis and killing 
of pathogens (3, 6).  
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 Macrophages and DCs differentiate from monocytes in the bone marrow 
and they are professional antigen presenting cells (APCs) (3, 7, 8). The 
differentiation could be triggered by different environmental cues. Once matured, 
they circulate into peripheral blood, spleen or lymph nodes (LNs) and present 
ingested antigens (Ags) to T or B cells as the link between innate and adaptive 
immunity. 
 
 Mast cells, neutrophils, eosinophils and basophils are granulocytes which 
all have granules in cytoplasm (7-13). However, each type of granulocytes 
contains distinct granules that function differently. Mast cells and basophils share 
similarities of function and morphology. Both mast cells and basophils have 
granules which contain chemical mediators like histamine, leukotrienes and 
heparin (11, 12). Activation through binding/crosslinking the surface receptors of 
immunoglobulin E (IgE) triggers the degranulation of mast cells and basophils and 
the release of chemical mediators cause atopic diseases. Thus, mast cells and 
basophils are two major types of innate immune cells involved in type 2 immunity 
(12). Chemical gradients of molecules like interleukin-8 (IL-8) and leukotrienes 
generated at infection sites are signals for neutrophils to phagocytose opsonized 
microbes or particles. On the other hand, neutrophils release cytokines and 
antimicrobial contents by degranulation to recruit additional immune cells to 
amplify the inflammatory responses (6). Eosinophils release cytokines and 
enzymes such as peroxidase, ribonuclease, prostaglandins and neurotoxin upon 
activation by factors like IL-5. Through the degranulation and release of cytokines 
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and enzymes, eosinophils facilitate killing of infected cells or pathogens (10). 
However, degranulation of eosinophils could cause problems during autoimmune 
or/and allergic diseases. 
 
Adaptive immunity 
 APCs are the fundamental link between innate and adaptive immunity (1-
3). Naïve T cells first develop in the thymus and the main types are CD4+ or CD8+ 
T cells.  Later they circulate into the peripheral sites such as blood or lymph nodes 
(LNs). APCs express class II MHC molecules which present antigenic peptides 
which will be recognized by T cell receptor (TCR) to activate CD4+ T cells and this 
process typically happens near the site of infection. Class I MHC is expressed by 
all nucleated cells and presents peptide Ags to CD8+ T cells. Development of B 
cells primarily happens in the bone marrow and they do not need MHC for 
activation or selection. There are two major classes of B cells: B1 and B2 cells 
(14). Marginal zone and follicular B cells are the two subclasses of B2 cells. B1 
progenitors in fetal liver give rise to B1 cells which are T cell independent, for they 
do not need help from T cells to produce antibodies (14). Antibodies produced by 
B1 cells are polyspecific and can bind to self or microbial Ags. B cell progenitors 
in the bone marrow differentiate into transitional B cells and later develop into B2 
cells. B2 cells give rise to either marginal zone or follicular lineages (14). Both T 
and B cells undergo positive and negative selection through different mechanisms 
to make sure they distinguish between self and non-self Ags. This is a critical 
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process to avoid autoreactive cell development and to create diverse T and B cell 
repertoires which could respond to different foreign Ags. 
  
CD8+ T cells are usually called cytotoxic T lymphocytes (CTLs) as they 
release granzyme and perforin containing granules to kill infected cells or tumor 
cells (15). Another subset of T cells are Natural killer T cells (NKT) which express 
NK receptors and invariant TCR. NKT cells are also important for adaptive immune 
responses. NKT cells produce cytokines such as IL-4, IL-9 and IFNγ and their roles 
have been identified in immune defense like viral infection and tumor immunity (16-
20).  
 
 A major function of the adaptive immune response is to produce highly 
specific antibodies (Abs) that bind to antigen (Ag) with high affinity and help 
eliminate pathogens and foreign substances. 
 
B cells which produce Abs for humoral immunity could produce five major 
classes of immunoglobulins: IgA, IgD, IgE, IgG and IgM. There are also several 
subtypes of IgA and IgG. Abs can mediate protection against pathogens by various 
means: 1) Ab-dependent cell-mediated cytotoxicity; 2) Ab triggered signal 
transduction leading to receptor activation; 3) Ab-mediated neutralization of free 
Ags; 4) Ab-mediated complement opsonization; 5) phagocytosis of opsonized 
pathogens. Ab isotype switch and long-lived plasma cell differentiation typically 
occurs within germinal centers (GCs), specialized immune responses located in 
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peripheral LNs and other secondary lymphoid organs. Several cell types contribute 
to the GC responses including follicular helper T, follicular regulatory T and 
follicular DCs. GC reactions of these cell types will be discussed in more detail 
below. 
 
CD4+ helper T cell subsets 
T helper cells (Th), or CD4+ T cells, is one major type of T cells which play 
essential roles in adaptive immune system. Their primary job is to provide help to 
other immune cells such as APCs and B cells through production of cytokines. The 
differentiation of different subsets of CD4+ T cells require several factors: 1) T cell 
receptor (TCR) signal from APCs through the presentation of pathogens by MHCII; 
2) costimulatory signals mediated by cell surface interactions; 3) cytokine 
environment which could trigger the signal transducer and activator of transcription 
(STAT), NF-κB or SMADs signaling pathways. These cytokine-specific activated 
signaling pathways further induce downstream transcription factors of each 
specific cell lineages. Each of the Th cells produce their own signature cytokines 
that providing either help or suppression to other immune cells. As showed in Fig. 
1, the major CD4+ subsets include but not limited to type 1 T helper (Th1), Th2, 
Th9, Th17, T follicular helper (TFH) and T regulatory (Treg) cells (21). Each type 
of Th cells has their own master transcription factors, requirements of 
differentiation, signature cytokine production and functions.  
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 Th1 cells are generated during intracellular infection by pathogens such as 
viruses or bacteria. APC produced IL-12 binds to the receptor to activate STAT4 
signaling which triggers the expression of the Th1 master transcription factor T-
box 21 (TBX21 or Tbet) (22). STAT4 together with Tbet promotes the 
differentiation of Th1 cells from naïve CD4+ T cells (23). The signature cytokine 
produced by Th1 cells is IFN-γ which could stimulate innate immune cells like 
macrophages to clear invading pathogens. 
 
 It is also significant that IFN-γ produced by Th1 cells further stimulates 
STAT1 pathway to strengthen Tbet expression (24). Th1 response is critical for 
pathogenic infection clearance while uncontrolled type 1 response leads to chronic 
inflammation or autoimmune diseases.  
 
 Th2 cells provide protection against extracellular parasites and Gata3 is the 
master transcription factor for Th2 cells (25). IL-4 activates the STAT6 pathway 
and subsequently induces GATA3 expression (26). IL-2 and thymic stromal 
lymphopoietin (TSLP) are the two other important cytokines mediating Th2 
differentiation through STAT5.  Th2 cells produce cytokines IL-4, IL-5 and IL-13 
which involve in atopic diseases. IL-4 promotes B cell production of IgE, the 
primary mediator of allergic diseases (27). 
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Figure 1: The differentiation of CD4+ T cell subsets and their functions. 
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 Similar to Th2 cells, Th9 cells mainly help eliminate extracellular pathogens 
such as helminths and parasites (28). Th9 cells also play critical roles in the 
development of allergic diseases like asthma (29). Transforming growth factor beta 
(TGFβ) together with IL-4 activate PU.1 and interferon regulatory factor 4 (IRF4) 
to promote the differentiation of Th9 cells (30). The major cytokine produced by 
Th9 is IL-9. IL-9 is a growth factor for mast cells and promotes IgE production by 
B cells (31, 32). Recent studies show that Th9 cells play critical roles in promoting 
antitumor immune responses (33-35).  
 
 Naïve CD4+ T cells differentiate into Th17 cells under the cytokine 
environment of IL-6, TGFβ and/or IL-23 (36). Cytokine activated STAT3 
upregulates the master regulator of Th17- retinoic acid receptor-related orphan 
receptor gamma t (RORγt) (37). Th17 cells produce IL-17 for the protection against 
fungi or bacteria and they are mainly located at mucosal surfaces. Th17 cells are 
the primary pathogenic immune cells in multiple autoimmune diseases such as 
rheumatoid arthritis, multiple sclerosis, lupus and psoriasis (38, 39).  
 
 Foxp3+ Treg cells are the fundamental suppressive cells that control 
immune tolerance (40, 41). Treg cells develop either the thymus or peripheral sites 
and the origins separate Treg into thymic Treg (tTreg) and peripheral Treg (pTreg) 
(42). The differentiation of pTreg requires TGFβ and IL-2 while nTreg development 
is more complex. Treg cells need IL-2 for their development and they express high 
level of the IL-2 receptor CD25. Foxp3 is the master transcription factor of all Treg 
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cells and is located on the X chromosome (43). The main function of Treg cells is 
to maintain immune tolerance through the production of IL-10, TGFβ and other 
suppressive cytokines (44). Deficiency of Treg or Foxp3 causes severe 
autoimmune and inflammatory diseases (45, 46). However, excessive Treg cells 
prevent the immune system from eliminating pathogens or expanding tumor cells 
(47, 48). Several studies have shown that TFR cells primarily differentiate from 
Foxp3+ Treg precursor cells (49-53), however, like TFH cells, TFR cells can also 
develop from naïve CD4 T cells (54). Tregs are generated either during T cell 
differentiation in the thymus (tTregs) or from mature CD4 T cells in the periphery 
(pTregs) (55, 56), but whether TFR cells preferentially develop from tTregs or 
pTregs is not known. TFR cells are discussed below in much more detail. 
 
 Naïve CD4+ T cells can also differentiate into follicular helper T cells (TFH) 
under the cytokine influence of IL-6 and IL-21. TFH cells are mainly located in 
germinal center and are a pivotal cell type that regulates B cell responses in the 
GC as discussed below in more detail.  
 
Germinal center reaction 
The GC is a cluster of rapidly proliferating and clonally expanding B cells 
where they undergo somatic hypermutation of immunoglobulin (Ig) genes, Ig 
affinity selection, and class switch recombination (Fig. 2 and Fig. 3) (57, 58). Long-
lived memory B cells and plasma cells are generated within GCs to produce high-
affinity Abs against pathogens. The master transcription factor for TFH cells, Bcl6, 
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is also highly expressed in GC B cells (59). Unique cell surface markers of GC B 
cells are GL7 and Fas (TNF receptor superfamily member 6) in additional to other 
markers such as IL21R, ICOSL and SLAM (60). Extensive studies have shown GC 
B cells closely interact with TFH cells to receive their help. Signals gathered from 
B cell Ag presentation to T cells such as CD40 and its ligand CD40L are essential 
for the development of GC B cells (61-64). It is well accepted that TFH cells are 
the primary source of CD40 signals within the GCs. Upon the recognition of 
cognate Ag, B and T cells are activated in the primary follicle and T cell zone, 
respectively (65). B and T cells interact with each other after their migration to the 
interfollicular region. Later, both B and T cells migrate into the follicle, the migration 
of B cells need the network with follicular DCs. Proliferating B cells within the follicle 
result in the formation of the early GC and it continues its expansion which leads 
to the establishment of the mature GC and typically this process takes about 7 
days (65). 
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Figure 2: Germinal center distribution and functions. Ab isotype switch and long-
lived plasma cell differentiation typically occurs within GCs, specialized immune 
responses located in peripheral LNs and other secondary lymphoid organs. 
Several cell types contribute to the GC responses including TFH, TFR and follicular 
DCs. The GC is a cluster of rapidly proliferating, clonally expanding B cells where 
somatic hypermutation of Ab genes and Ab affinity selection takes place. Most GC 
B cells die and the GC determines the long-term outcome of the high affinity Ab 
response. 
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Figure 3: TFH and TFR cells both act in the germinal center (GC) to regulate the 
generation of antigen-specific antibody-secreting cells. Historically, TFR cells were 
considered to only suppress TFH and GC B cells, however, work in this thesis 
alters that idea. TFH cells differentiate from conventional CD4 T cells after 
activation with Ag and DC presentation. TFR cells differentiate from conventional 
Treg cells and migrate into the GC. 
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There are two highly organized zones within the GCs: the dark zone and 
light zone (65). B cells located in the dark zone are called centroblast while light 
zone B cells are centrocytes (66). TFH and follicular DCs provide positive signals 
to centrocytes for selection in the light zone and positively selected GC B cells 
cycle into dark zone to proliferate and acquire mutations, after which centroblast 
cycle back to light zone for selection again. Several cytokines have been reported 
as key regulators of GC zones. IL-21, produced primarily by TFH cells in the GCs, 
plays essential roles in instructing the cycle transition from centrocyte to 
centroblast while another TFH-produced cytokine, IL-4, is required for the 
acquisition of the centrocyte state (67). Recently, Craft and colleagues showed 
that the regulatory cytokine IL-10, which is produced by TFR cells is also important 
for the development of GC B cells. Specifically loss of TFR-derived IL-10 directly 
caused the loss of dark zone (68).  
 
T follicular helper cells 
A specialized subset of differentiated CD4+ T cells, TFH cells, are required 
in the germinal center reaction to help B cells generate high affinity Abs to Ag (69, 
70). TFH cells control the initiation as well as the outcome of the GC B cell 
response (71-74). TFH cells are critical for the proper production of protective Abs 
during an infection, however, the over-production of TFH cells can also lead to 
autoimmunity since TFH cells can help B cells to produce self-reactive Abs (74-
76). Thus, the proper regulation of TFH cell differentiation is essential both for 
normal immune function and for preventing autoimmune disease. 
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During an immune response, Ag-activated CD4 T helper cells that up-
regulate the expression of the transcription factor Bcl6 and down-regulate the 
transcription factor Blimp1 develop into TFH cells. The function of TFH cells is to 
promote formation of GCs and select B cell clones that produce high-affinity Abs 
(reviewed in (51, 69-71, 77)). TFH cells are commonly identified as CD4+ CXCR5+ 
and PD-1+ T cells. TFH cells have an activated effector T cell phenotype but do 
not express the high affinity IL-2 receptor (IL2R, also known as CD25). TFH cells 
control the outcome of the GC B cell response, and are critical for memory B cell 
and plasma cell development. TFH cells produce IL-21, a cytokine that potently 
promotes B cell activation and Ab secretion. While TFH cells are required for the 
production of high affinity Abs, excessive numbers of TFH cells can promote 
autoimmunity by helping B cells produce self-reactive Abs (74-76).  The proper 
regulation of TFH cell differentiation is therefore essential for strong ab responses 
and preventing development of autoimmune disease (75, 76).  
 
The transcription repressor BCL6 is a 95-kDa nuclear phosphoprotein (78). 
It contains a POZ/BTB domain at the N-terminus, three PEST domains in the 
central region and six Zinc Finger motifs by its C-terminus (78, 79). The POZ/BTB 
domain recruits several co-repressors while Zinc Finger motifs bind to specific 
promoter DNA sequences of target genes to repress transcription (78). Bcl6 is the 
master transcription factor of TFH cells, as overexpression of BCL6 favors 
differentiation of CD4 T cells into TFH cells. TFH cell differentiation is completely 
blocked in Bcl6 conditional deleted T cells while other effector helper T cells are 
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relatively unaffected (80-82). It remains largely unknown why a naïve CD4 T cell 
develops into a TFH cell instead of other helper cell types (TH1, TH2, TH17) when 
it is activated in vivo. How the master transcription factor Bcl6 is induced during 
TFH cell differentiation also need to be fully elucidated. We wondered if 
metabolism controlled Bcl6 expression and TFH differentiation as previous reports 
showed that mature TFH cells have a unique limited metabolic activity compared 
to other effector T helper cells (83).  
 
The stable activation of Bcl6 expression in CD4+ T cells during TFH cell 
differentiation has to overcome two critical impediments: 1) Bcl6 strongly auto-
represses its own expression (84, 85), and 2) IL-2 produced during T cell activation 
inhibits Bcl6 expression (86-90). BCL6 auto-represses itself and this requires the 
co-repressor CTBP (C-terminal-binding protein) which associates with BCL6 in the 
Bcl6 promoter region (84). CTBP is regulated by NAD+ and NADH levels, which 
means it could be affected by metabolic stress (91, 92). Thus lowering NADH 
levels under metabolic stress potentially removes CTBP from binding with Bcl6 
which reduces Bcl6 auto-repression. TFH-like cells can be produced in vitro with 
human CD4 T cells and STAT3/STAT4-activating cytokines plus TGFβ (93). 
However, these same signals do not promote mouse TFH cell differentiation, and 
in particular TGFβ plays different roles in mouse versus human CD4 T cell 
differentiation (93). Recently, Cyster and colleagues found that during an immune 
response, DCs can up-regulate expression of the IL2R in order to inhibit IL-2 
signaling by CD4+ T cells and thus promote TFH cell differentiation (94). While this 
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DC-IL2R mechanism appears to be important for early TFH cell differentiation, 
more work is needed to understand the relevance of this pathway in different 
immune settings. Another mechanism for blocking IL-2 in vivo to promote TFH cell 
differentiation involves IL2R-expressing Treg cells (95). The significance of this 
pathway in different immune settings is also unclear.  Another potential pathway 
for controlling IL-2 during the T cell response is through glycolysis, since 
decreased glycolysis leads to decreased cytokine translation (96). 
 
Despite a great deal of investigation into Bcl6 function in CD4+ T cells, the 
precise mechanisms by which Bcl6 promotes TFH cell differentiation have not 
been fully elucidated. One major mechanism proposed for Bcl6 in the control of 
TFH cell differentiation is that Bcl6 inhibits terminal CD4+ T cell differentiation by 
repressing the Prdm1 gene that encodes the transcription repressor Blimp1 (51, 
70, 82, 87, 97). Blimp1 is a potent inhibitor of TFH cell differentiation, and IL-2 
suppresses TFH cell differentiation largely through induction of Blimp1 expression 
(51, 87, 89). However, the mechanism by which Blimp1 itself represses TFH cell 
differentiation is not settled. Bcl6 is a direct target of Blimp1, and Bcl6 expression 
is repressed by Blimp1 (82, 98, 99). Thus, Blimp1 may inhibit TFH cell 
differentiation by simply repressing Bcl6 expression. At the same time, Blimp1 may 
repress other genes apart from Bcl6 that are critical for the TFH cell fate or TFH 
cell differentiation. Additionally, it has been proposed that Blimp1 promotes 
terminal T cell differentiation, which may indirectly promote differentiation away 
from a less differentiated TFH cell state (51, 70). Adding to the complexity of this 
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pathway is that Blimp1 represses Bcl6, which promotes TFH cell differentiation, 
but also represses genes that inhibit TFH cell differentiation, such as Il2, Ifng and 
Tbx21 (Tbet) (98, 100). Thus Blimp1 can potentially either promote or inhibit TFH 
cell differentiation.  
 
Although it is generally accepted that Bcl6 promotes TFH cell differentiation 
by repressing certain key genes (101, 102), the complete set of TFH cell 
differentiation genes regulated by Bcl6 have not been fully characterized and the 
overall process is not well understood. Since Bcl6 is a dedicated transcriptional 
repressor, genes that are turned on in TFH cells such as CXCR5, IL-21 and PD-1 
must be regulated indirectly by Bcl6. In principle then, Blimp1 may repress the key 
genes required for TFH cell differentiation, and the critical function of Bcl6 in TFH 
cell differentiation may be to repress the anti-TFH cell activity of Blimp1. A hybrid 
model is that Blimp1 and Bcl6 each control different aspects of TFH cell 
differentiation, so that neither factor fully controls TFH cell differentiation 
independent of the other.  
 
Mice deficient in Bcl6 or Blimp1 have not provided a clear answer as to the 
relationship between of Blimp1 and Bcl6 in the development of TFH cells (82, 103). 
Using conditional knockout (cKO) mouse models, researchers have shown that 
loss of Bcl6 in T cells results in complete loss of TFH cell development, while, 
conversely, Blimp1 cKO mice have increased TFH cell populations.  
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One important gene that can be used to assess Bcl6 and Blimp1 regulation 
patterns is Pdcd1, which encodes PD-1, a common marker for TFH cells. Bcl6 is 
known to promote PD-1 expression (104), and Blimp1 is a strong repressor of PD-
1 (105). Since Bcl6 is a transcriptional repressor, the mechanism that Bcl6 uses to 
up-regulate PD-1 expression is likely to be an indirect pathway, such as by 
repressing the transcription of a gene which normally represses Pdcd1 
transcription. Therefore, one possibility is that Bcl6 promotes PD-1 expression 
primarily by repressing Blimp1-mediated transcriptional repression of Pdcd1. 
 
T follicular regulatory cells 
GC B cell responses are also regulated by T follicular regulatory (TFR) cells, 
which developed from Treg cells and localized to the GC (49, 50, 106-111)(Fig. 2 
and 3). TFR cells are generally thought to limit the function of TFH cells in the GC 
(49, 50, 106-108, 111). TFR cells, like TFH cells, are dependent upon the 
transcriptional repressor protein Bcl6 for their development, but unlike TFH cells 
express the canonical Treg master regulatory transcription factor Foxp3 (49, 50, 
106-111). The overall function of TFR  cells is poorly understood, however the 
prevailing model for TFR cell function currently in the field is that TFR cells repress 
excessive TFH and GC B cell proliferation and promote the selection of high affinity 
B cells (49, 50, 106-108, 111).  
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Differentiation and regulation of TFR cells 
Several studies have shown that TFR cells primarily differentiate from 
Foxp3+ Treg precursor cells (49-53)(Fig. 4), however, like TFH cells, TFR cells 
can also develop from naïve CD4 T cells (54). Tregs are generated either during 
T cell differentiation in the thymus (tTregs) or from mature CD4 T cells in the 
periphery (pTregs)(55, 56), but whether TFR cells preferentially develop from 
tTregs or pTregs is not known. Tregs in the intestinal mucosa are predominantly 
pTregs that develop in response to Ags derived from microbiota and diet as a 
tolerance mechanism (55, 56). TFR cells that develop in the gut lymphoid tissues 
such as Peyer’s patches may therefore differentiate from pTregs, and so ultimately 
may have a naïve CD4+ T cell origin. Interestingly, Peyer’s patch TFR cells have 
a markedly different transcriptome than peripheral lymph node TFR cells, possibly 
suggesting a different origin (112). 
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Figure 4: Cell surface receptors and transcription factors involved in TFR cells 
differentiation and function. nTreg cells differentiate into TFR cells when mTorc1 
signal is increased while IL-2 signal is decreased. Blue colored proteins are known 
cell surface marker expressed on Tregs or TFR cells; green colored proteins are 
unique surface markers expressed by TFR cells; red colored CD25 is highly 
expressed on the surface of non-TFR Tregs but not TFR cells. 
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TFR cells express TFH cell surface markers such as PD-1, CXCR5 and 
ICOS, Treg surface markers such as CTLA-4 (cytotoxic T-lymphocyte-associated 
protein 4) and GITR (glucocorticoid-induced TNFR-related protein) and the master 
regulatory transcription factors for both Tregs (Foxp3) and TFH cells (Bcl6) (49, 
50, 106, 109, 113). Thus, TFR cells display a hybrid or mixed TFH/Treg phenotype. 
Most studies have analyzed TFR cells in the mouse, but phenotypically similar 
TFR cells have also been described for humans (114, 115) and macaques (116). 
TFR cells also express significant levels of Blimp1 (49, 117). Notably, TFR cells 
express lower CD25 (the expression of CD25 on TFR cells is only about 50% of 
the expression of total Tregs) compared with non-TFR Tregs (109, 115). Together 
with Bcl6, Nfat2 (nuclear factor of activated T-cells 2) upregulates CXCR5 
expression on Treg cells and enables them to migrate to GC, take on the follicular 
phenotype and become TFR cells (49, 50, 106, 109, 118). Recent work showed 
that mTorc1 is essential in regulating the conversion of Treg to TFR cells and this 
is potentially through a Stat3-Tcf-1-Bcl6 pathway (119, 120). Our lab has also 
specifically found that in contrast to TFH cells which can develop in the absence 
of Stat3, Stat3 is essential for TFR cell development (110). 
 
Ag exposure triggers the differentiation of TFR cells and this process is DC-
dependent (49, 50, 54, 113). Sage et al. used mice that express diphtheria toxin 
receptor (DTR) specifically on DCs to test this (107). DC-depletion led to 
substantially decreased TFR cells, however it is unknown which specific DC 
subsets directly contribute to TFR cell differentiation. At the same time, PD-1-
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ligand expressed on DCs has an inhibitory role on TFR cell development (121). 
Treg cells can repress the function of APCs including DCs (122), but whether TFR 
cells can affect DCs or other APCs and how this might affect the GC response is 
unknown. Precisely what Ags and signals that Tregs respond to in order to become 
TFR cells is not well understood. TFR cells respond more strongly to self-Ags than 
foreign Ags, which fits with the self-reactive nature of tTregs (54, 123). While TFR 
cells can develop to have specificity for the immunizing Ag (54), a recent study on 
the TCR specificity of TFH and TFR cells indicated that in contrast to TFH cells, 
TFR cells do not proliferate well to the cognate Ag after immunization (53). 
Furthermore, an analysis of TCR gene sequences in TFH and TFR cells indicated 
that TFH cells are a sub-population of cells related to naïve CD4+ T cells, whereas 
TFR cells showed a TCR profile very similar to the total Treg cell population (53). 
These findings are consistent with a model that TFH cells are Ag-specific T cells 
that proliferate after Ag stimulation, while TFR cells develop in a polyclonal and 
Ag-independent manner from Tregs. Therefore, TFR cells either develop from 
Tregs in a polyclonal TCR-dependent response involving recognition of self-Ag, or 
TFR cells expand and differentiate through a Ag-independent and TCR 
independent pathway (e.g. Jagged1 plus Ox40 stimulation (124)). Note that the 
Maceiras et al (53) analyzed TFR cells from peripheral LNs, and the TCR 
specificity of Peyer’s patch TFR cells may be more similar to naïve CD4+ T cells 
that are responsive to gut Ags. 
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T cell co-stimulation is required for TFR cell differentiation as either CD28 
or ICOS deficiency leads to reduction of TFR cells (49, 113, 125). Mice with CD28 
deficiency specifically in Treg cells (using Foxp3-cre) had a large reduction in TFR 
cells in the draining lymph node (dLN) after NP-OVA immunization (125). This is 
largely due to the roles of CD28 in inducing Foxp3 expression as well as TFR cell 
proliferation (49, 126-129). Similarly, TFR cell development is abrogated in ICOS 
deficient mice (113). ICOS signaling modulates the expression of Bcl6 and c-Maf 
in TFH cells and might play a similar role in TFR cells (130-132). Bcl6 is an 
essential transcription factor for TFR cells, and recent studies suggest that c-Maf 
is also pivotal for TFR cell differentiation (49, 50, 109, 133, 134). Bcl6 and Blimp1 
reciprocally repress expression of the other factor in both TFH and TFR cells (82, 
117). The regulation of TFH cell differentiation by Blimp1 is Bcl6 dependent while 
Blimp1 controls TFR cell differentiation independent of Bcl6 (117). One mechanism 
for Bcl6-independent Blimp1 activity may relate to regulation of Nfat2, which has 
been shown to be important for up-regulation of CXCR5 on TFR cells as well as 
for expression of PD-1 (105, 118). Blimp1 has been shown to repress Nfat2 
expression (105), and thus Blimp1 could have a suppressive role for CXCR5 and 
PD-1, both of which are key genes increased in TFR cells. Increased expression 
of Nfat2 in Blimp1-deficient regulatory T cells could then lead to Bcl6-independent 
expression of CXCR5 and PD-1, and appearance of TFR–like cells (117). TFR 
cells were repressed by high IL-2 levels at the peak of influenza infection and this 
was through a Blimp1-dependent mechanism (135). IL-2 is also a negative signal 
for Bcl6 expression, and decreased IL-2 promotes induction of TFR cells. After the 
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peak anti-flu virus immune response, CD25 expression is downregulated in some 
Treg cells while Bcl6 is increased, leading to TFR programming (135). Thus, IL-2 
is a key factor regulating TFR differentiation, promoting Blimp1 expression while 
repressing Bcl6 in Treg cells to preclude TFR cell development.  
 
PD-1, which is expressed by both TFH and TFR cells, inhibits TFR 
differentiation and their suppressive function (49, 50, 111, 113). Sage et al. showed 
that TFR cells in Pdcd1-deficient mice had greater suppressive function and 
resulted in decreased Ab production both in vitro and in vivo (113). The exact 
mechanism for the increased inhibitory function of Pdcd1-deficient TFR cells 
remains unclear. At the same time, PD-1 ligand (PD-L1) is required for TFR cell 
generation, however it is not clear if this is a direct or indirect effect on TFR cells 
(54). Similarly, CTLA-4, the inhibitory receptor which binds to CD80 and CD86, 
limits the differentiation of TFR cells (108, 136, 137). However, restricted CTLA-4 
deficiency in Treg cells contributes to not only enhanced TFR cells, but also 
enhanced TFH, GCB cells and Ab responses (137). One explanation is that in the 
absence of CTLA-4 function in Tregs, there is uncontrolled inflammation that drives 
higher TFH cell and GCB responses. However, since it is not clear what drives the 
enhanced TFH, GCB and IgE responses, a “helper” role of TFR cells cannot be 
completely excluded (137). Deletion of CTLA-4 results in increased IL-10 
production by Tregs (138). Since IL-10 can promote GC responses (68, 139), it is 
possible that increased IL-10 production by TFR cells contributes to the increased 
GC and Ab response in CTLA-4 KO mice. 
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The majority of research on TFR cells has been conducted in the mouse 
models but a few studies have elucidated that TFR cell populations in human GCs 
are basically similar to TFR cells in mice (115, 140, 141). CXCR5+ TFH-like cells 
in blood, also known as circulating TFH (cTFH) cells, are typically used as a proxy 
marker for the GC TFH cell response in humans, and by assessing cTFH cell 
levels, a large number of genes controlling TFH cell development in humans have 
been categorized in patients with known specific monogenic mutations (142). 
Circulating TFR (cTFR) cells are also used as a correlate of the TFR cell response 
in humans (114, 143-146), however in contrast to TFH cells (142), only two genes 
that control TFR cell development and function in humans have been 
characterized to date: LRBA and CTLA4 (146-148). Thus, more work is needed to 
fully understanding specific genes and pathways that regulate human TFR cells. 
 
Suppressive functions of TFR cells 
TFR cells have been described in the literature mainly as suppressors of 
the GC reaction and the Ab response, repressing the proliferation of TFH cells and 
GC B cells, and limiting the generation of Ab-secreting cells and overall Ab 
responses. However, the experimental approaches taken in many studies may 
give rise to alternative interpretations. In vitro, TFR cells can suppress the 
proliferation and cytokine production of TFH cells as well as the proliferation and 
Ig secretion of B cells, similar to the in vitro suppressive function seen with non-
TFR Tregs (108, 113-115, 123, 149). In vivo studies have demonstrated that TFR 
cells, analyzed initially by depletion of total Tregs, can suppress the numbers of 
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GC B cells and TFH cells (49, 50, 106, 108, 113, 137). However, these studies 
may not represent specific effects of TFR cell depletion or physiological TFR cell 
function. Total Treg deletion (49, 50, 95, 108) provokes severe inflammation and 
causes a very broad effect on T cell responses, thus obscuring the specific 
functions of TFR cells. Studies using adoptive transfer of TFR cells along with other 
T cells into T cell deficient mice or TFH-cell deficient mice might have non-
physiological effects due to the abnormal immune environment of the recipient 
mice (49, 50, 113, 119). Studies where TFR cell numbers are greatly enhanced 
due to deletion of Roquin (120), or  where Tregs are forced to migrate to the B cell 
follicle by ectopic CXCR5 expression (118) might also lead to non-physiological 
suppression and/or non-specific suppression of GC responses. Mice with the Nfat2 
gene deleted in Tregs with Foxp3-cre showed a partial loss of TFR cells and 
augmented numbers of GC B cells, TFH cells and Ag-specific Abs after 
immunization (118).  However, a more general loss of Treg function by loss of 
Nfat2 affecting TFH cell expansion cannot be discriminated from the specific 
effects from loss of TFR cells. In vitro studies of TFR cells cannot mimic the 
complex in vivo environment of the GC reaction and cannot analyze affinity 
selection of GC B cells. Together, a re-interpretation of the TFR cell literature helps 
explain why the function of TFR cells assessed using Bcl6FC mice (68, 109, 135), 
is strikingly different from many other studies on TFR cell function. 
 
Nonetheless, it is clear that under some conditions, TFR cells can 
negatively regulate the GC reaction, and the precise mechanisms that TFR cells 
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use to negatively regulate the GC are unsolved questions in the TFR cell field. 
Treg cells can suppress immune responses by multiple known mechanisms: IL-2 
consumption, secretion of inhibitory factors (IL-10, TGFβ, IL-35, granzyme B, 
CD39, CD73, TRAIL) and CTLA-4-mediated inhibition of TFH cell co-stimulation 
(150-152). Of these known suppressor factors, we can narrow down mechanisms 
for TFR cells based on previous data. TFH cell differentiation is inhibited by IL-2 
(86, 87, 89), and IL-2 consumption by TFR cells could be predicted to help stabilize 
TFH cell responses. However, TFR cells have low levels (lower compared with 
normal Treg) of the high affinity IL-2 receptor CD25 (109), which indicates a 
lessened capacity to compete for available IL-2. IL-10 is unlikely to be the key 
suppressor factor, since IL-10 is a stimulatory or growth factor for GC B cells (68), 
and further, IL-10 expression by TFH cells is increased in the absence of TFR cells 
in Bcl6 mice (109). IL-35 is unlikely to be a TFR suppressor factor as it primarily 
affects T cell proliferation (153), and data with Bcl6FC mice do not indicate an 
effect of TFR cells on the number of TFH cells (109). Granzyme B is unlikely as a 
major mechanism as it is decreased in TFR cells compared to Tregs (49). 
Metabolic suppressor pathways such as CD39 and CD73 have not been 
extensively characterized and are possible effectors of suppression by TFR cells 
as they could potentially affect cell proliferation in the GC. In mice, TGF-β is known 
to stabilize TFH cell responses (154), and prevent excess TFH cell responses 
(155). In humans, TGF-β is required for TFH cell differentiation (93). A lack of TGF-
β signaling from loss of TFR cells does not clearly explain the normal TFH cell 
numbers in the presence of increased TFH cytokine expression in Bcl6FC mice 
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(109). TRAIL is cytotoxic to follicular B cell lymphomas, which have a GC 
phenotype (156), but otherwise there is no data about TRAIL activity in GCs, 
particularly regarding TFR cells. CTLA-4 expression by TFR cells may inhibit the 
ability of TFH cells to receive key co-stimulation signals from GC B cells, thus 
limiting TFH cell and thus TFH cell-driven GC B cell expansion. Unfortunately, 
studies on the role of CTLA-4 function in TFR cells are difficult to interpret, as 
discussed above (108, 136, 137).  
 
A recently described mechanism for TFR cells to inhibit TFH cells and the 
GC is secretion of a decoy IL-1 receptor that inhibits TFH cell differentiation (123). 
This pathway appears to be most critical during early TFH cell activation and 
differentiation rather than during the GC reaction itself. Furthermore, data pointing 
to this decoy IL-1 receptor pathway being used specifically by TFR cells to control 
TFH cells in vivo is lacking. Another potential pathway used by TFR cells to control 
TFH cells and GC B cells is the inhibitory receptor TIGIT (T cell immunoreceptor 
with Ig and ITIM domains), that is important for Treg suppressive function (109) 
(157). Intriguingly, the two major suppressive pathways utilized by TIGIThigh Tregs 
are IL-10 and Fgl2 (Fibrinogen-like protein 2)(157). Fgl2 is a secreted protein that 
binds the inhibitory IgG receptor FcγRIIB (158). As noted above, it is unlikely that 
loss of IL-10 from TFR cells contributes to the deregulated cytokine expression of 
TFH cells. Thus, Fgl2 may be a key factor used by TFR cells to regulate GC B 
cells. Interestingly, FcγRIIB KO mice are known to develop lupus (159), and Fgl2 
KO mice develop glomerulonephritis, a pathologic manifestation of auto-Abs in 
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severe lupus disease also seen in IgA nephropathy (160, 161). Fgl2 KO mice have 
Treg cell defects, but the GC response in these mice has not been characterized 
(160). TIGIT+ Tregs can also affect cell activation by inducing tolerogenic DCs via 
CD155 (162). But currently, data on TFR cells controlling the GC via TIGIT is 
lacking. 
 
In analyzing mice with deletions of Bcl6 or Stat3 specifically in the Treg 
lineage (Bcl6FC and Stat3FC mice, respectively), we found noteworthy differences 
between how TFR cells are regulated by Stat3 and Bcl6 (109, 110). While TFR 
cells are strongly depleted in both Bcl6FC and Stat3FC mice (109, 110), there are 
significant differences in the phenotype. First, in Bcl6FC but not Stat3FC mice, 
TFH cells produce higher levels of cytokines compared to control mice. Second, 
Ag-specific IgA is increased in Bcl6FC mice whereas Ag-specific IgG is increased 
in Stat3FC mice (109, 110). At the same time, TFH cell and GC B cell numbers 
are not altered in either Bcl6FC or Stat3FC mice compared to control mice (109, 
110). The function of Stat3 in TFR cells is not understood. Analogous to TFH cells 
(163, 164), Stat3 may be important for TFR cell development by inducing Bcl6 
expression in Treg cells in response to cytokines such as IL-6 and IL-21. Stat3 
expression is also activated in TFR cells by the mTorc1 pathway (119). Bcl6 is 
required for the development of the CXCR5+PD-1+ follicular T cell phenotype, and 
the induction of Bcl6 by STAT factors may be essential for both TFR cell as well 
as TFH cell development. If this is the case though, why does deletion of Stat3 in 
Foxp3-expressing cells produce a different phenotype than deletion of Bcl6 in 
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Foxp3-expressing cells? Why are cytokines up-regulated from TFH cells in Bcl6FC 
mice but not in Stat3FC mice? The answers to these questions are currently 
unknown but are essential for fully understanding TFR cell development and 
function. One possible explanation for the difference is that there is a larger 
population of residual TFR cells in Stat3FC mice compared to Bcl6FC mice and 
these residual TFR cells in Stat3FC mice are enough to negatively regulate TFH 
cells. Thus, there is a greater deletion of TFR cells in Bcl6FC mice, leading to a 
more complete loss of repression by TFR cells, and thus increased TFH cell 
activity. The increased TFH cell cytokines in Bcl6FC mice might promote the 
elevated IgA response that is not seen in Stat3FC mice. In summary, in the Bcl6FC 
model, TFR cells repress TFH cell activity but not proliferation. Why Ag-specific 
IgG is increased in Stat3FC mice is unclear, but possibly the residual TFR cells in 
Stat3FC mice have augmented GC helper activity. 
 
Role of TFR cells in autoimmune disease 
An important area where TFR cells have a clear suppressive effect on the 
GC and Ab response, even in Bcl6FC mice, is in suppression of auto-Abs that drive 
autoimmune disease (109, 118, 125, 135, 165). This role of TFR cells in 
suppressing auto-Ab production was elucidated most thoroughly by Fu et al. who 
showed that Bcl6FC mice developed late-onset Sjogren’s-like autoimmune 
disease and autoimmunity could be induced in young mice by immunizing mice 
with salivary gland extracts (165). The precise mechanisms for how TFR cells can 
suppress auto-Abs while at the same time promote the Ab response to foreign Ags 
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remains unexplored. One possible explanation is that since TFR cells, like Tregs, 
have a bias towards self-Ag recognition (53, 54, 123), they are able to inhibit self-
reactive TFH cells that might develop in the GC by competing with them for 
recognition of self-Ags on GC B cells and binding and blocking B7 co-stimulatory 
receptors via CTLA-4. Little is known about the role of TFR cells in human 
autoimmune disease, but increased levels of circulating TFR (cTFR) cells are 
observed in patients with Sjogren’s disease (114, 143) and systemic lupus 
erythematosus (144). Interestingly, an increased ratio of cTFR to cTFH cells is 
strongly associated with more severe disease in the case of Sjogren’s syndrome 
(143). Whether high levels of cTFR cells simply represent the presence of active 
GC responses or whether cTFR cells are especially elevated in autoimmune 
disease is not clear. The data on Sjogren’s cTFR cells is particularly hard to 
interpret since the cells have an immature CD25+ TFR phenotype and their 
relationship to GC-localized TFR cells is unclear (143).   
 
“Helper” functions of TFR cells 
Although Tregs themselves are overwhelmingly described as suppressor 
cells, there are several reports that Tregs can promote immune responses in 
certain circumstances. Under inflammatory conditions or in mice with mutations in 
genes that affect Foxp3 expression, a fraction of Tregs can become “ex-Tregs” 
and differentiate into pro-inflammatory cells (166, 167). Surprisingly, ex-Tregs can 
also convert into functional TFH cells in Peyer’s patches (168) and in 
atherosclerosis (169).  
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The first published characterization of TFR cells in 2009 by Linterman et al 
showed that TFR cells had a key “helper” role in terms of helping TFH cells select 
high affinity Ag-specific B cell clones (75). In their proposed model, TFR cells 
restrict the outgrowth of non-Ag-specific B cell clones in the GC, presumably 
allowing for more efficient interaction of TFH cells with selection of specific high-
affinity Abs (75).  At the same time, the Linterman et al data can also be interpreted 
as showing evidence for a major helper function for TFR cells in the GC. For 
instance, a significant decrease in Ag-specific GC B cells is observed after total 
Treg depletion whereas total GC B cells increased (75). This can be interpreted as 
two distinct processes: 1) loss of TFR cells leads to a loss of TFR cell helper activity 
and thus reduced Ag-specific GC B cells, and 2) because total Tregs are depleted, 
there is a massive increase in GC responses to commensals and self-Ags— 
responses that are normally inhibited by Tregs. Even though these latter 
commensal-specific and self-Ag-specific GCs may be weakened by loss of TFR 
cell helper activity, the large number of these responses leads to a total increase 
in GC B cells.  
 
A different Treg-TFH helper pathway was shown by León et al., who found 
that Tregs are required for the normal anti-influenza TFH cell response (95). In this 
study, ex-Tregs were not converting into TFH cells, and León et al. proposed a 
mechanism where CD25+ Tregs take up IL-2 and limit the overall availability of IL-
2, thereby promoting TFH cell differentiation (95). Importantly however, León et al. 
did not investigate loss of TFR cells (which would occur with Treg depletion) as a 
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mechanism for the Treg helper effect, and their data does not eliminate a helper 
role for TFR cells in the TFH/GC response in the virus infection system. 
 
Because of the problems associated with deleting total Tregs and the lack 
of specific and robust models to deplete TFR cells in vivo, we developed Bcl6FC 
mice (109). In these mice, TFR cell development is specifically blocked without a 
loss in total Tregs or Treg function (109). We determined that loss of TFR cells led 
to a significantly decreased IgG response and that TFR cells were required to 
produce the highest affinity Ag-specific Abs (109). These results are consistent 
with a critical helper role for TFR cells in the GC. In our published results, we did 
not observe a loss of GC B cells or TFH cells in Bcl6FC mice despite the decreased 
IgG response (109). This could be due to the time-point where we analyzed the 
GC or the type of Ag used to induce the GC.  
 
In 2017, Laidlaw et al presented very clear evidence that TFR cells can act 
as essential helper cells in the GC (68). In this study, mice were infected with 
lymphocytic choriomeninigitis virus (LCMV) and the GC and Ab response analyzed 
(68). Importantly, Laidlaw et al used Bcl6FC mice and Treg-specific IL-10 cKO 
mice to demonstrate that TFR cells are a critical source of IL-10 in the GC and that 
IL-10 drives the growth of GCs by promoting entry of GC B cells into the dark zone 
(68). In the absence of IL-10-producing TFR cells, GC B cell numbers and the 
LCMV-specific Ab response were decreased (68). A recent study with malaria 
infection in mice also showed that IL-10 was critical for the maintenance of the GC 
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and GC-derived Ab response (139). Overall, these recent findings strongly support 
the idea that IL-10-producing TFR cells have a major role in maintaining the GC 
reaction and thus act as “helper cells”. In our lab, we have been using Bcl6FC mice 
and analyzing the role of TFR cells in a food allergy model with peanut Ag. In this 
model, we find that TFR cells help maintain the peanut-specific GC response and 
IgE response. TFR cells thus appear to have a key role in allergic immune 
responses, represent a novel target for allergy-specific immunotherapy. 
 
Research goals 
Because of the complexity of Bcl6 regulation, the potential for regulation of 
IL-2 expression via glycolysis and the fact that TFH cells have an unusual state of 
low metabolism for effector T cells (170), we pursued the idea that Bcl6 expression 
and TFH cell differentiation are uniquely controlled by metabolic signals.  
 
Additionally, due to the complexity of the interplay between transcription 
factors Bcl6 and Blimp1, the critical function of Bcl6 in TFH cell differentiation may 
be to repress the anti-TFH cell activity of Blimp1. A hybrid model is that Blimp1 
and Bcl6 each control different aspects of TFH cell differentiation, so that neither 
factor fully controls TFH cell differentiation independent of the other. Using 
conditional knockout mouse models, researchers have shown that loss of Bcl6 in 
T cells results in complete loss of TFH cell development, while, conversely, Blimp1 
cKO mice have increased TFH cell populations. Here we used conditional 
knockout mice doubly deficient for both Bcl6 and Blimp1 in T cells to delineate the 
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respective roles of these two key factors in TFH cell differentiation and PD-1 gene 
expression.  
 
TFH cells have been identified as an important cell population that regulate 
allergic reactions and IgE through the production of IL-4. The model for TFR cell 
function currently is that TFR cells repress excessive TFH and GC B cell 
proliferation and promote the selection of high affinity B cells. Specifically, the role 
of TFR cells in the IgE pathway is not clear. Here, we investigated the role of TFR 
cells in IgE production and GC reactions using a variety of mouse models. 
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MATERIALS AND METHODS 
Mice 
C57BL/6J mice were obtained from Jackson labs and then bred in house. 
Bcl6fl/fl mice (88) were backcrossed to CD4-cre transgenic mice (171) and the 
C57BL/6 strain for at least six generations and then crossed to Prdm1fl/fl mice (172, 
173). Foxp3-YFP-cre (WT), Foxp3-YFP-cre Bcl6fl/fl (Bcl6FC) mice were previously 
described (109). B6.129(Cg)-Foxp3tm3(DTR/GFP)Ayr/J (Foxp3-DTR), B6(SJL)-
Il10ratm1.1Tlg/J (Il10rafl/fl), B6.129S7-Rag1tm1Mom/J (Rag1 KO), B6.129P2-
Il10tm1Cgn/J (IL-10 KO), Tbx21-/- mice, and IL-2 knockout mice were obtained 
from Jackson Laboratories. Foxp3-YFP-cre Ptenfl/fl (PtenFC) mice were previously 
described (174). Prdm1-fl/fl mice were backcrossed to Foxp3-YFP-cre transgenic 
mice and the C57BL/6 strain for at least six generations to generate Foxp3-YFP-
cre Prdm1fl/fl (Blimp1FC) (117). MB1-cre Bcl6fl/fl (MB1-Bcl6-/-) mice were obtained 
from Dr. Marion Pepper (Univ. Washington). Il10rafl/fl mice were backcrossed to 
MB1-cre mice to generate or MB1-cre Il10rafl/fl (MB1-Il10ra-/-) mice. Il10rafl/fl mice 
were also backcrossed to CD4-cre to generate CD4-cre Il10rafl/fl (CD4-Il10ra-/-) 
mice. For Bcl6FC, Blimp1FC or PtenFC mice, Foxp3-YFP-cre only mice were used 
as WT controls. For MB1-Il10ra-/- or CD4-Il10ra-/- mice, Il10rafl/fl only mice were 
used as controls. Bcl6fl/fl only mice were used as controls for CD4-BCL6cKO mice. 
Male and female mice of 6-12 weeks old were used. Mice were bred under specific 
pathogen-free conditions at the laboratory animal facility at Indiana University 
School of Medicine and were handled according to protocols approved by the 
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Indiana University School of Medicine Institutional Animal Use and Care 
Committee (IACUC). Mouse strains used in all studies are listed in Table 1. 
Table 1: Experimental models: mouse strains 
Strain Original Source Strain Code 
Wild type (C57BL/6J) The Jackson Laboratory JAX 000664 
B6.129S(FVB)-
Bcl6tm1.1Dent/J (Bcl6 Flox) 
The Jackson Laboratory JAX 023727 
B6.129-Prdm1tm1Clme/J 
(Blimp1 Flox) 
The Jackson Laboratory JAX 008100 
B6.129(Cg)-
Foxp3tm4(YFP/icre)Ayr/J 
(Foxp3-YFP WT) 
The Jackson Laboratory JAX 016959 
B6.129(Cg)-
Foxp3tm3(DTR/GFP)Ayr/J 
(Foxp3-DTR) 
The Jackson Laboratory JAX 016958 
B6(SJL)-Il10ratm1.1Tlg/J 
(Il10ra Flox) 
The Jackson Laboratory JAX 028146 
B6.129S7-Rag1tm1Mom/J 
(Rag1 KO) 
The Jackson Laboratory JAX 002216 
B6.129P2-Il10tm1Cgn/J (IL-10 
KO) 
The Jackson Laboratory JAX 002251 
B6.129S6-Tbx21tm1Glm/J 
(Tbet KO) 
The Jackson Laboratory JAX 004648 
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C.129P2(B6)-Il2tm1Hor/J (IL-2 
KO) 
The Jackson Laboratory JAX 002229 
B6.129S4-Ptentm1Hwu/J 
(Pten Flox) 
The Jackson Laboratory JAX 006440 
B6.C(Cg)-
Cd79atm1(cre)Reth/EhobJ 
(Mb1-Cre) 
The Jackson Laboratory JAX 020505 
Foxp-Cre Bcl6 fl/fl (Bcl6FC) In House N/A 
Foxp-Cre Pten fl/fl (PtenFC) In House N/A 
Foxp-Cre Prdm1 fl/fl (Blimp1FC) In House N/A 
Foxp-Cre Prdm1 fl/fl Bcl6 fl/fl 
(DKO) 
In House N/A 
CD4-Cre Bcl6 fl/fl (CD4-
BCL6cKO) 
In House N/A 
CD4-Cre Prdm1 fl/fl (CD4-
Blimp1cKO) 
In House N/A 
CD4-Cre Bcl6 fl/fl Prdm1 fl/fl 
(CD4-dcKO) 
In House N/A 
Mb1-Cre Bcl6 fl/fl  In House N/A 
Mb1-Cre Il10ra fl/fl In House N/A 
CD4-Cre Il10ra fl/fl In House N/A 
CD4-Cre Bcl6 fl/fl IL-2KO (cIL2) In House N/A 
39 
Foxp-Cre Bcl6 fl/fl IL-2KO 
(IL2BFC) 
In House N/A 
 
Immunizations, depletion of Treg cells and Ab administration 
For NP-KLH (Keyhole Limpet Hemocyanin) immunization, mice were 
intraperitoneally (i.p.) injected with 100 μg NP (175)-KLH (Biosearch 
Technologies) and were sacrificed at the indicated day. For AICAR (5-
Aminoimidazole-4-carboxamide ribonucleotide) NP-KLH immunization, 5-10 mg 
AICAR (Sigma-Aldrich) was mixed with 100 μg NP (175)-KLH in PBS and the 
mixture was injected i.p., similarly to Andris et al (176). For SRBC immunization, 
mice were intraperitoneally (i.p.) injected with 1 x 109 SRBCs (Rockland 
Immunochemicals) and were sacrificed at the indicated day. For food allergy 
challenge, mice were starved for two hours followed by feeding with 300 µl per 
mouse 1.5% NaHCO3 water intragastrically on indicated dates. Half hour after 
NaHCO3 treatment, mice were sensitized with 1 mg per mouse of peanut extract 
(Greer Laboratories) or ovalbumin (Sigma-Aldrich) together with 10 µg per mouse 
of cholera toxin (Sigma-Aldrich) (177). Mice were sacrificed on indicated days and 
serum, mesenteric LNs and spleens were harvested. For facial survival bleeding, 
about 0.3 ml blood was collected each mouse per time from the submandibular 
vein on indicated dates. Foxp3+ cells were deleted by administering 1 µg 
diphtheria toxin (DT) in PBS per mouse intraperitoneally into Foxp3-DTR mice on 
indicated dates. For the IL-10R blocking study, 200 μg of anti-IL-10R Ab (1B1.3A; 
Bioxcell) or control rat IgG1 (HRPN; Bioxcell) were injected i.p. into female C57Bl/6 
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mice every 3 days starting on day 1 after first intragastric (i.g.) peanut challenge. 
Serum was collected from the submandibular vein bleeding. Mice were subjected 
anaphylaxis at day 36. 
 
Mouse T cell culture 
Naïve CD4+ T cells were isolated from the spleen via isolation kit (Miltenyi 
Biotec). Cells were activated with plate-bound anti-CD3 (10 μg/ml; 145-2C11; Bio 
X Cell) and anti-CD28 (10 μg/ml; 37.51; Bio X Cell) for 72 hours in culture medium, 
at 1 X 106 cells/ml. Culture medium was glucose-free Dulbecco's Modified Eagle 
Medium (DMEM) media (Gibco/LifeTechnologies) supplemented with 10% 
dialyzed fetal bovine serum (FBS), Penicillin/Streptomycin, glutamine, non-
essential amino acids, 10 mM HEPES and 55 uM β-mercaptoethanol. 10 mM 
glucose from a 1M stock solution (Gibco/LifeTechnologies) was added to the 
cultures where indicated. For IL-2 addition experiments, 100 U/ml of recombinant 
human IL-2 (rhIL-2) was added into culture medium as indicated. RhIL-2 was 
obtained from the Biological Resources Branch (BRB), Division of Cancer 
Treatment and Diagnosis (DCTD), National Cancer Institute-Frederick Cancer 
Research and Development Center (NCI-FCRDC). For primary cultures, cells were 
treated with indicated doses of 2-deoxyglucose (2DG; Sigma) for the duration of 
the culture. For secondary stimulation, after activation for 48 hours in complete 
medium cells were harvested and washed once with PBS. And cells were re-
stimulated on plates coated with anti-CD3 and anti-CD28 with indicated medium 
for another 48 hours. Cells were treated with indicated doses of AICAR for 48 hours 
41 
or Compound C (Cayman Chemical) for last 24 hours during re-stimulation. EL4 
cells were cultured with indicated medium for 72 hours. Cells were harvested for 
gene expression or flow cytometric staining. Medium supernatants were collected 
for indicated cytokine analysis. CD25+ Treg cells were isolated from the spleen 
from naïve mice via isolation kit (Miltenyi Biotec). Foxp3+YFP+ cells were further 
isolated by Fluorescence-activated cell sorting (FACS). Cells were stimulated for 
72 hours with plate-bound anti-CD3/anti-CD28 Abs and supernatants were 
collected to measure IL-10 concentration. 
 
Retrovirus production and transduction 
Platinum E cells (Cell Biolabs) were grown in 10 ml of Dulbecco’s modified 
eagle medium 1640 (DMEM 1640) with 10% FBS and 1% antibiotics in a 100 mm 
tissue culture dish. When confluency reached 80~90%, cells were transfected with 
control vector or retroviral vector containing genes encoding Bcl6 and Tbx21 using 
lipofectamine 3000 (Thermo Fisher Scientific). For transfection, 18 μg of vector, 6 
μg of pCL-Eco and 25 μl of P3000 were mixed in 500 μl of Opti-MEM®I reduced-
serum medium (Thermo Fisher Scientific), and 25 μl of lipofectamine 3000 was 
mixed in another 500 μl of Opti-MEM®I. After combining, this mixture was 
incubated for 10-15 mins at room temperature (RT). The mixture was gently 
pipetted into culture dish. After 16 hours, the media containing retrovirus was 
collected and changed with new fresh media. After 24 hours, the media was 
collected and centrifuged at 1500 rpm for 5 mins to remove cell debris. 
Supernatant containing retrovirus was used for retroviral transduction or stored at 
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-80 °C for subsequent use. For retrovirus transduction, CD4 T cells were isolated 
from the spleen via isolation kit (Miltenyi Biotec). Cells were activated with plate-
bound anti-CD3 (10 μg/ml; 145-2C11; Bio XCell) and anti-CD28 (10 μg/ml; 37.51; 
Bio XCell) for 24 h at 1 X 106 cells/ml. Activated mouse CD4+ T cells were infected 
with retrovirus containing control or expressing the interested gene by 
centrifugation at 2300 rpm at 32oC for 90 mins in the presence of 8 μg/ml polybrene 
(Sigma-Aldrich). For co-infection experiments, either control H2Kk or Bcl6-H2Kk-
expressing (178) RVs were co-transduced with either control GFP or Tbet-GFP–
expressing (179) RVs. After spin infection, supernatants were substituted with 
fresh medium containing 10 U/ml recombinant human IL-2. Two days later, cells 
were collected for flow cytometric staining, or isolated by FACS for gene 
expression analysis.   
 
Human naive CD4 T cell isolation and culture  
Cryopreserved human peripheral blood mononuclear cells (PBMCs) from 
unidentified healthy donors were thawed in a 37°C water bath, then washed twice 
with pre-warmed complete RPMI 1640 culture medium. Naive CD4 T cells were 
isolated using the “human naive CD4 T cell isolation kit” from Miltenyi Biotec (San 
Diego, CA) per manufacturer’s instructions. Human T cell activation beads (anti-
CD3/CD28) from Invitrogen were added at 1:1 ratio. Cells were then split into 
different culture conditions at the density of 5x105 cells/mL, cultured in a 48-well 
tissue culture plate with either complete RPMI-1640 supplemented with 10% heat-
inactivated FBS and 100 U/ml penicillin/streptomycin, or glucose-free RPMI 
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supplemented with 10% dialyzed FBS and 100 U/ml of penicillin/streptomycin. 
Cells were treated with different concentrations of 2DG or AICAR and cultured in 
complete RPMI medium at 37 °C with 5% CO2 incubator for 4 days. For some 
cultures, cells were cultured in the presence of TFH-skewing human recombinant 
cytokine cocktail (1 ng/ml of IL-12, 5 ng/ml of TGF-β, and 25 ng/ml of IL-6; all from 
R&D Systems), Harvested cells were subjected to both flow cytometry and RT-
QPCR analysis for TFH cell-specific protein markers and genes respectively. 
 
Flow cytometry reagents 
Following labelled Abs were used: anti-CXCR5 (L138D7), anti-PD-1 
(29F.1A12), anti-CD4 (RM4-5), anti-FOXP3 (MF-14), anti-CXCR4 (L276F12), anti-
CD86 (GL-1), anti-CD38 (90), anti-Granzyme B (GB11), anti-Klrg1 Ab 
(2F1/KLRG1) and anti-B220 (RA3-6B2) were obtained from BioLegend; Anti-
mouse CXCR5 (2G8), GL7 (GL7),  anti-Eomes (Dan11mag), anti-BCL6 (K112-91) 
for mouse T cells and anti-TBET (4B10) were from BD Biosciences. Anti-human 
CD4 (OKT4), anti-human BCL6 (BCL-UP), anti-human CD279/PD-1 (J105), anti-
human CD185/CXCR5 (MU5UBEE) and fixable viability dye were purchased from 
eBioscience. Fixable viability dye, anti-CD38 and anti-Foxp3 (FJK-16s) Abs were 
from eBioscience. Fluorescent Abs for flow cytometric analysis are listed in Table 
2. Annexin V Ab was obtained from BioLegend. 
Table 2: Fluorescent antibodies for flow cytometric analysis 
Antigen/Name Clone Fluorochrome Company Cat. No. 
Mouse 
RM4-5 PERCPCY5.5 BioLegend 100540 
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CD4  PECY7 BioLegend 100528 
CXCR5 L138D7 PE BioLegend 145504 
CXCR5 L138D7 PECY7 BioLegend 145516 
PD-1 29F.1A12 APC BioLegend 135210 
FOXP3 FJK-16s FITC eBioscience 53-5773-82 
MF-14 Pacific Blue BioLegend 126410 
MF-14 FITC BioLegend 126406 
GZMB GB11 Pacific Blue BioLegend 515408 
EOMES Dan11mag PERCP-
eFlour 710 
eBioscience 46-4875-82 
Perforin EBioOMAK-D PE eBioscience 12-9392-82 
GL7 GL7 Alexa Flour 
647 
BD Pharmingen 561529 
CD38 90 eFlour 450 eBioscience 48-0381-82 
90 APCCY7 BioLegend 102728 
90 Pacific Blue BioLegend 102720 
B220 RA3-6B2 PERCPCY5.5 BioLegend 103236 
RA3-6B2 APCCY7 BioLegend 103224 
IgA Ma-6E1 PE eBioscience 12-4204-82 
IgE RME-1 PE BioLegend 406908 
IgG1 RMG-1 PECY7 BioLegend 406614 
KLRG1 2F1 eFlour 450 eBioscience 48-5893-80 
2F1 PERCPCY5.5 BioLegend 138418 
H2Kk 36-7-5 PE BioLegend 114907 
36-7-5 FITC BioLegend 114905 
GATA3 16E10A23 APC BioLegend 653806 
Annexin V  PE BioLegend 640908 
BCL6 K112-91 PE-CF594 BD Biosciences 562401 
CD19 6D5 Pacific Blue BioLegend 115523 
6D5 PE BioLegend 115508 
6D5 PECY7 BioLegend 115520 
CXCR4 L276F12 PE BioLegend 146506 
CD86 GL-1 APCCY7 BioLegend 105030 
Fixable 
Viability Dye 
N/A eFlor 780 eBioscience 65-0865-14 
Fixable 
Viability Dye 
N/A eFluor 450 eBioscience 65-0863-14 
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Human 
PD-1 EH12.2H7 APC BioLegend 329908 
 eBioJ105 PE eBioscience 12-2799-42 
CXCR5 RF8B2 FITC BD Pharmingen 558112 
BCL6 BCL-UP APC eBioscience 17-9880-42 
 
Cell staining for flow cytometry 
Cell suspensions from mLNs and/or spleens were prepared and filtered 
through a 40-µm cell strainer (Fisherbrand). Cells were washed and diluted in PBS 
with 1% FBS and were stained with Fc block (BioXCell) for 5 min, followed by 
surface staining for the indicated markers. For intracellular staining, after surface 
markers were stained, cells were fixed and stained with Abs against transcription 
factors by following Foxp3 fixation kit (eBioscience) protocols. Human cells were 
subjected to surface staining with appropriate fluorochrome-conjugated Abs for 30 
min on ice. After wash, cells were stained with viability dye for 5 min at room 
temperature before fixation and permeabilization 1h at room temperature followed 
by the intracellular staining with APC-conjugated mouse anti-BCL6 Ab 30 min in 
the dark. Cell events were collected on an LSR II flow cytometer (Becton 
Dickinson) and analyzed with FlowJo software. 
 
Assessment of anaphylaxis 
To assess anaphylaxis, 2 mg peanut extract protein without cholera toxin 
was administered intraperitoneally per mouse four weeks post the second 
immunization (day 36). Mice were monitored for 50 mins after challenge for rectal 
(core) body temperature change (Braintree Scientific). After 50 mins, whole blood 
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was collected into EDTA (Ethylenediaminetetraacetic acid) coated tubes (BD 
Microtainer) and hematocrit values were determined by an Element HT5 
Veterinary Hematology Analyzer (HESKA). Clinical scores were evaluated at 20 to 
30 mins after challenge as reported (6). Basically, 0, no clinical signs; 1, scratching 
around the head and nose; 2, reduced activity with increased respiration; 3, 
wheezing and lying prone; 4, no response after prodding and convulsion; and 5, 
death. 
 
Antibody measurement and cytokine ELISAs 
Ab titers of SRBC-specific or anti-NP-KLH IgG titers in serum were 
measured by ELISA, as previously reported (110). Briefly, 96 well Nunc-Immuno 
plates (Sigma-Aldrich) were coated with SRBC membrane protein or NP-KLH 
overnight at 4oC. Wells were blocked with 1% Bovine serum albumin (BSA) and 
diluted serum was added and incubated at room temperature for 2 h. A peroxidase-
conjugated anti-mouse IgG1 (BD), anti-IgG2b (BD), anti-mouse IgG or anti-mouse 
IgM Abs (Sigma-Aldrich) were used as secondary Ab. Titers of peanut-specific Ab 
in serum were measured by ELISA, as previously reported (180). For peanut-
specific IgE, 96 well Nunc-Immuno plates (Sigma) were coated with IgE Ab (LO-
ME-3, BIO-RAD) overnight at 4oC. Wells were blocked with 1% BSA and diluted 
serum was added and incubated at room temperature for 2 hours. Peanut extract 
protein was labelled with biotin (Sigma-Aldrich) and added for one hour followed 
by adding poly-HRP streptavidin (Pierce Endogen) for half hour. For peanut-
specific IgG1, 96 well Nunc-Immuno plates were coated with 5 ug/ml peanut 
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extract protein overnight at 4oC. Wells were blocked with 1% BSA and diluted 
serum was added and incubated at room temperature for 2 hours. An anti-mouse 
IgG1 (BD Pharmingen) was used as secondary Ab with avidin-HRP. IL-2 or IL-10 
concentrations of medium supernatants were measured with the mouse IL-2 or IL-
10 ELISA kit from BD Biosciences, following the manufacturer’s protocol. Primary 
and secondary Abs for ELISA are listed in Table 3. 
Table 3: ELISA capture and biotinylated secondary antibodies 
Capture Ab. Clone Final 
Concentration 
Company Cat. No. 
IgE R35-72 2 µg/ml BD PH 553413 
IgE LO-ME-3 5 µg/ml BIO-RAD MCA419 
Secondary 
Ab. 
Clone Dilution 
Factor 
Company Cat. No. 
IgG1 A85-1 1: 250 BD Pharmingen 553441 
IgG2b R12-3 1: 250 BD Pharmingen 553393 
IgG2a R19-15 1: 250 BD Pharmingen 553388 
IgG2c-HRP heavy chain 1: 250 SouthernBiotech 1078-05 
IgA-HRP α-chain specific 1: 1000 Sigma-Aldrich A4789 
IgM-HRP μ-chain specific 1: 1000 Sigma-Aldrich A8786 
IgG-HRP whole molecule 1: 1000 Sigma-Aldrich A9044 
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RNAseq 
On day 36 after peanut and cholera toxin challenge, CD4+ T cells were 
isolated from the spleen from mice using CD4 T cell Macs isolation kit (Miltenyi 
Biotec). Cells were stained for TFH and TFR markers (CD4, CXCR5 and PD-1) 
and TFH, TFR cells were isolated by FACS. Total RNA was collected from sorted 
TFR cells using the RNeasy Plus Micro kit (QIAGEN) for mRNA sequencing. 
RNAseq and sequences analysis was performed by the Indiana University School 
of Medicine Center for Medical Genomics. For isolation of Klrg1+ cells, mice were 
immunized with SRBC and TFH cells sorted as above but anti-Klrg1 Ab 
(2F1/KLRG1) was also used for staining. Total RNA was collected from freshly 
sorted cells using the RNeasy Plus Micro kit (QIAGEN). 
 
Gene expression analysis 
Total RNA was prepared using the QIAGEN RNeasy Mini Kit following the 
manufacturer’s protocol. Quantitative PCR (QPCR) reactions were carried using 
TaqMan™ Fast Advanced Master Mix (Applied Biosystems) with commercially 
available specific Taqman primers (Life Technologies). Samples were run in 
duplicates and the QPCR assays were run on the Applied Biosystems real-time 
QPCR machine. Mouse samples used β-tubulin (tubb5) as the reference gene, 
and human samples used GAPDH. Taqman probes used for qPCR are listed in 
Table 4. 
Table 4: Taqman probes for qPCR 
Mouse 
Gene Cat. No. 
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Tubb5 Mm00495806_m1 
Bcl6 Mm00477633_m1 
Il2ra Mm00434260_m1 
Il2 Mm00434256_m1 
Pdcd1 Mm01285676_m1 
Cxcr5 Mm00432086_m1 
Prdm1 Mm00476128_m1 
Il10 Mm00439614_m1 
Il4 Mm00445259_m1 
Il21 Mm00517640_m1 
Gzmb Mm00442837_m1 
Tbx21 Mm00450960_m1 
Ifng Mm01168134_m1 
Eomes Mm01351984_m1 
Il12a Mm00434169_m1 
Human 
Gene Cat. No. 
BCL6 Hs00153368_m1 
CXCR5 Hs00540548_s1 
PDCD1 Hs01550088_m1 
ICOS Hs00359999_m1 
 
RNAseq and bioinformatic analysis 
RNAseq and sequence analysis was performed by the Indiana University 
School of Medicine Center for Medical Genomics. The RNAseq analysis was 
conducted using a standard workflow including sequence alignment and feature 
counts, then followed by differential expression analysis. First, raw reads of RNA-
seq sets were mapped by using an alignment tool, STAR (181), to the UCSC Mus 
musculus genome (mm10) downloaded from the GENCODE (182). Then feature 
Counts (183) was adopted to assign uniquely mapped reads to genes according 
to the UCSC mm10 annotation file obtained from igenomes 
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(https://support.illumina.com/sequencing/sequencing_software/igenome.html). 
After removing low expressed genes which had less than 0.5 counts per million 
(CPM) in more than 12 out of 16 samples, we normalized gene expression across 
all samples. The dissimilarity between samples based on their gene expression 
profile was examined by multidimensional scaling (MDS) plot. The EdgeR software 
program (184) was employed to perform differential expression analysis for 
different comparisons. Differentially expression genes (DEGs) were determined if 
their p-values after multiple-test correction with FDR-adjustment were less than 
0.05 and the amplitude of fold changes (FCs) were larger than 1.8. 
 
Statistical analysis 
All data analysis was done using Prism GraphPad software.  Unless 
otherwise stated, Student t test or ANOVA with Tukey post hoc analysis were used. 
Only significant differences (P < 0.05) are indicated in Figures. 
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RESULTS 
PART I: AMP Kinase Promotes Bcl6 Expression and Follicular Helper T Cell 
Differentiation in both Mouse and Human T cells 
 
Bcl6 is regulated by glycolysis 
Because of the complexity of Bcl6 regulation, the potential for regulation of 
IL-2 expression via glycolysis and the fact that TFH cells have an unusual state of 
low metabolism for effector T cells (83), we pursued the idea that Bcl6 expression 
and TFH cell differentiation is uniquely controlled by metabolic signals. Since 
blocking glycolysis during T cell activation results in an inhibition of cytokine mRNA 
translation, such that secretion of IFN-γ and IL-2 is markedly decreased (96), we 
reasoned that blocking glycolysis might play a role during TFH differentiation, by 
blocking inhibitory IL-2 production. Initially, as in Chang et al (96), we activated 
wild-type (WT) naïve CD4 T cells in glucose versus galactose medium, but we did 
not observe significant differences in Bcl6 expression (data not shown). However, 
as a control, we also activated naïve CD4 T cells in medium without added glucose 
or galactose, analyzed Bcl6 mRNA expression by QPCR. As shown in Fig. 5A, 
compared to T cells activated in 10 mM glucose, Bcl6 was increased about 10-fold 
when the T cells were activated in the absence of added glucose. This was 
accompanied by an up-regulation of Bcl6 protein, as measured by intracellular 
staining and flow cytometry (Fig. 5B). We tested if a transformed T cell line showed 
this same regulation of Bcl6 by glucose withdrawal, and so we tested the EL4 
lymphoma cell line by culturing the cells with glucose or without glucose. We 
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observed a similar increase in Bcl6 mRNA after 48 hours in glucose-deprived 
conditions, and protein was increased as well as analyzed by flow cytometry (Fig. 
5 C, D). We then tested the effect of the non-metabolizable glucose analogue 2DG 
when it was added to naïve CD4 T cells activated in DMEM medium containing 
glucose. As shown in Fig. 5E, Bcl6 mRNA increased over 4-fold when metabolism 
of the normal glucose in the culture is inhibited by 2DG.  Because the effect of 
complete glucose deprivation (GD) on Bcl6 induction was much stronger than the 
effect with 2DG, we chose to focus on GD for further studies. Note, our medium 
contains glutamine that can be used as an alternative energy source for T cells 
(185, 186), though there is increased cell death and decreased proliferation in the 
absence of glucose. We wondered if glucose withdrawal was inhibiting T cell 
activation, therefore we analyzed IL-2 (Il2) and IL-2 receptor alpha (Il2ra) chain 
gene expression. As shown in Fig. 6A and B, in the absence of glucose, naïve 
CD4 T cells still become activated to transcribe levels of Il2 and Il2ra mRNAs 
comparable to that with glucose conditions. However, consistent with published 
findings that inhibition of glycolysis leads to an inhibition in cytokine translation 
(96), IL-2 was secreted at significantly lower levels in T cells activated under GD 
conditions than that under glucose conditions (Fig. 6C). Nonetheless, substantial 
levels of IL-2 were still secreted under GD conditions (Fig. 6C). 
  
53 
 
Figure 5: Induction of Bcl6 by blocking glycolysis. Naïve CD4+ T cells isolated from 
C57BL/6 mice or EL4 cells were cultured in complete (GLU+) or glucose (GLU-) 
deprivation medium. Cells were harvested for total RNA preparation or flow 
cytometric staining. (A) Relative mRNA expression was determined by quantitative 
RT-PCR. Bcl6 gene expression from isolated naïve CD4+ T cells cultured under 
complete or glucose deprivation medium for 72 h (n = 3, mean ± SEM). (B) Flow 
cytometry histogram plot for Bcl6and mean fluorescence intensity (MFI) of naïve 
CD4+ T cells cultured under complete or glucose deprivation medium (n = 3, mean 
± SEM). (C) Bcl6 gene expression from EL4cells cultured under complete or 
glucose deprivation medium for 48 h (n = 3, mean ± SEM). (D) Flow cytometry 
histogram plot for Bcl6 and MFI of EL4 cells cultured undercomplete or glucose 
deprivation medium (n = 3, mean ± SEM). (E) Bcl6 gene expression from isolated 
naïve CD4+ T cells cultured under complete medium with or without20 mM 2DG 
for 72 h (n = 3, mean ± SEM). *p < 0.05, ***p < 0.001 (t test). Data are 
representative of 2 independent experiments of each time point with similar results.  
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Figure 6: Effects of blocking glycolysis on IL-2 and its receptor. Naïve CD4+ T cells 
isolated from C57BL/6 mice were cultured in complete (GLU+) or glucose (GLU-) 
deprivation medium for 72 h, cells were harvested for total RNA preparation and 
medium supernatants were collected for ELISA analysis. (A) Relative mRNA 
expression was determined by QPCR. Il2ra gene expression from T cells cultured 
under complete or glucose deprivation medium for 72 h (n = 3, mean ± SEM). (B) 
Il2 gene expression from T cells cultured under complete or glucose deprivation 
medium for 72 h (n = 3, mean ± SEM). (C) IL-2 concentration of medium 
supernatants harvested from complete or glucose deprivation cell culture after 72 
h (n = 3, mean ± SEM). NS (not significant, p > 0.05, t-test), ***p < 0.001 (t test). 
Data are representative of 2 independent experiments of each time point with 
similar results. 
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We wondered if the decreased IL-2 in the GD conditions leads to the 
increased Bcl6 levels. We then tested whether adding exogenous IL-2 could down-
regulate the induction of Bcl6 in T cells seen with GD, by supplementing the GD 
cultures with high levels of recombinant human IL-2. However, the added IL-2 had 
no effect on Bcl6 (Fig. 7A). Since it is difficult to determine if the added human IL-
2 was added to an inhibitory level equivalent to that made by T cells in glucose 
added conditions, we sought another approach to test this question. In order to 
stringently test the role of IL-2 in the GD effect on Bcl6, we used T cells from IL-2-
deficient (KO) mice. When activated in vitro, IL-2 KO T cells have a higher level of 
Bcl6 expression than WT T cells, likely due to their inability to produce IL-2 (data 
not shown). We then activated naïve CD4 T cells from IL-2KO mice in plus glucose 
or GD conditions (Fig. 7B). When IL-2 was added to the IL-2 KO T cells activated 
in plus glucose conditions, Bcl6 was sharply decreased, whereas addition of a 
similar amount of IL-2 to IL-2 KO T cells activated in GD conditions did not 
significantly decrease Bcl6 expression (Fig. 7B). These data indicate that the 
activating effect of GD on Bcl6 expression is dominant over the inhibition by IL-2. 
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Figure 7: Up-regulation of BCL6 by glucose deprivation is insensitive to IL-2-
mediated inhibition of Bcl6. Naïve CD4+ T cells isolated from C57BL/6 or IL-2 KO 
mice were cultured under complete (+GLU) or glucose (GLU-) deprivation media 
for 72 h, with or without addition of 100 U/ml recombinant human IL-2. Cells were 
harvested for total RNA preparation and relative mRNA expression was 
determined by QPCR. (A) Bcl6 gene expression from C57BL/6 naïve CD4+ T cells 
cultured under complete or glucose deprivation medium with or without rhIL-2 
addition for 72 h (n = 3, mean ± SEM). (B) Bcl6 gene expression from IL-2 KO 
naïve CD4+ T cells cultured under complete or glucose deprivation medium with 
or without rhIL-2 addition for 72 h (n = 3, mean ± SEM). NS (not significant, p > 
0.05, two-way ANOVA), ***p < 0.001 (two-way ANOVA). Data are representative 
of 2 independent experiments of each time point with similar results.  
57 
One pitfall of Bcl6 induction by GD is that lack of glucose during T cell 
activation prevents the strong T cell expansion that normally occurs during Ag 
stimulation in vivo. We therefore wondered if we could induce Bcl6 by GD in a 
secondary stimulation, after an initial stimulation and expansion in glucose-
containing media. We thus conducted an experiment where naïve CD4 T cells 
were activated in plus glucose media, and then after 2 days, collected, washed, 
and re-activated under either plus glucose or GD conditions. As shown in Fig. 8A, 
Bcl6 transcript is strongly induced in secondary stimulation under GD conditions. 
The transcript for the activation/TFH marker PD-1 (Pdcd1) was also up-regulated 
under GD conditions along with Bcl6 (Fig. 8B), whereas the transcript for Blimp-1 
(Prdm1) was not markedly increased (Fig. 8C). However, the key TFH marker 
CXCR5 was not increased in GD conditions compared to plus glucose. We then 
stained cells cultured in the secondary stimulation condition for Bcl6 (Fig. 8D, E), 
Tbet (Fig. 8F) and Foxp3 (Fig. 8G), and found that only Bcl6 was increased 
following GD. These data show that part of the TFH phenotype (Bcl6 and PD-1) 
can be induced during an ongoing T cell response if glucose in the immune 
environment is depleted while T cells are still being stimulated through the TCR, 
suggesting a novel pathway for TFH cell differentiation during the immune 
response. 
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Figure 8: Up-regulation of BCL6 by glucose deprivation works with secondary re-
stimulation and is specific for BCL6. Naïve CD4+ T cells isolated from C57BL/6 
mice were cultured with complete media for 48 h on anti-CD3 and anti-CD28 
coated plate, cells were collected and washed once with PBS and cultured under 
complete (GLU+) or glucose (GLU-) deprivation medium for another 48 h on anti-
CD3 and anti-CD28 coated plate. Cells were harvested for total RNA preparation 
or flow cytometric staining. (A) Relative mRNA expression was determined by 
QPCR. Bcl6 gene expression from isolated naïve CD4+ T cells cultured under 
complete or glucose deprivation medium during re-stimulation (n = 3, mean ± 
SEM). (B) Pdcd1 gene expression from isolated naïve CD4+ T cells cultured under 
complete or glucose deprivation medium during re-stimulation (n = 3, mean ± 
SEM). (C) Prdm1 gene expression from isolated naïve CD4+ T cells cultured under 
complete or glucose deprivation medium during re-stimulation (n = 3, mean ± 
SEM). (D) and (E) Bcl6 MFI of naïve CD4+ T cells cultured under complete or 
glucose deprivation medium during re-stimulation (n = 3, mean ± SEM). (F) Tbet 
MFI of naïve CD4+ T cells cultured under complete or glucose deprivation medium 
during re-stimulation (n = 3, mean ± SEM). (G) Foxp3 MFI of naïve CD4+ T cells 
cultured undercomplete or glucose deprivation medium during re-stimulation (n = 
3, mean ± SEM). *p < 0.05, ***p < 0.001 (t test). Data are representative of two 
independent experiments with similar results.  
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Bcl6 and the TFH response is regulated by AMP kinase 
Next, we wanted to explore the signaling pathway that leads to induction of 
Bcl6 expression after GD. The major metabolic sensor for GD is Adenosine 
Monophosphate-activated Protein Kinase (AMPK), which is activated by elevated 
Adenosine monophosphate (AMP) or Adenosine diphosphate (ADP) levels (187, 
188). Several drugs have been developed that target AMPK; compound C is a 
small molecule inhibitor of AMPK activity, and the AMP analog AICAR activates 
AMPK (189, 190). We thus tested the activity of AMPK in regulating Bcl6 
expression using these compounds. As shown in Fig. 9A, naïve CD4 T cells 
secondarily activated under GD conditions induce strong Bcl6 expression as 
expected, but this up-regulation of Bcl6 can be reversed by compound C treatment. 
Furthermore, AICAR stimulates significant Bcl6 expression in naïve CD4 T cells 
secondarily activated (Fig. 9B) in the presence of glucose. Taken together, these 
data indicate that AMPK has key role in Bcl6 regulation in CD4 T cells. Previously, 
AMPK was shown to positively regulate BCL6 transcription in human endothelial 
cells, by a mechanism involving inactivation of PARP1 (191). To our knowledge, 
the data here is the first data linking BCL6 and AMPK in T cells. Previously, it was 
shown that AICAR could act as an adjuvant in mice, to enhance Ab responses 
(176), however TFH cell responses were not specifically analyzed in this study. 
We therefore repeated this experiment, by injecting mice with the Ag KLH either 
with or without AICAR. As shown in Fig. 10A, in WT mice, AICAR significantly 
enhanced the anti-KLH IgG titer by about 3-fold. We then tested if this Ab response 
was driven by TFH cells, using T cell specific Bcl6 cKO mice (80). Loss of Bcl6 in 
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T cells completely ablates development of TFH cells and GC B cells. When cKO 
mice were immunized, the overall Ab response was lower, and AICAR did not 
boost the Ab response to any degree (Fig 10A). These data indicate that AICAR 
specifically enhances the TFH cell-dependent Ab response. To more carefully 
analyze if AICAR affected TFH cells, we analyzed responding T cells in immunized 
mice at days 3, 7 and 14 after immunization with KLH or KLH plus AICAR. 
However, AICAR did not significantly enhance the frequency or number of TFH 
cells induced by immunization (Fig. 10B and data not shown), although the 
percentage of TFH cells was slightly higher following AICAR. However, we did 
observe that within the TFH cells, Bcl6 expression was significantly enhanced by 
AICAR (Fig. 10C). This data is consistent with our in vitro work showing that AICAR 
can enhance BCL6 expression. Additionally, AICAR significantly increased the 
number of GC B cells (Fig. 10D), which may be the result of more potent TFH cell 
activity due to higher Bcl6 expression, or due to a separate effect of AICAR on B 
cells. 
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Figure 9: AMPK promotes BCL6 up-regulation, both in the presence or absence of 
glycolysis. Naïve CD4+ T cells isolated from C57BL/6 mice were cultured with 
complete media for 48 hours on anti-CD3 and anti-CD28 coated plate, cells were 
collected and washed once with PBS and cultured under complete or glucose 
deprivation medium for another 48 hours on anti-CD3 and anti-CD28 coated plate. 
Relative mRNA expression was determined by quantitative RT-PCR.  (A) Different 
doses of Compound C were added to cells for the last 24 hours of re-stimulation 
culture. Bcl6 gene expression from isolated naïve CD4+ T cells cultured under 
complete or glucose deprivation medium with or without the addition of Compound 
C during re-stimulation (n=3, mean ± SEM). (B) Different doses of AICAR were 
added to cells for the 48 hours of re-stimulation culture. Bcl6 gene expression from 
isolated naïve CD4+ T cells cultured under complete medium with or without the 
addition of AICAR during re-stimulation (n=3, mean ± SEM). *p < 0.05, ***p < 0.001 
(two-way ANOVA). Data are representative of two independent experiments with 
similar results.  
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Figure 10: AICAR enhances BCL6 and TFH-dependent Ab responses in vivo. (A) 
C57BL/6 mice were immunized i.p. with 100 μg NP-KLH or 100 μg NP-KLH plus 
10 mg AICAR and tested for in vivo Bcl6 level on day 3 post immunization. Bcl6 
MFI of splenic TFH cells on day 3 post immunization (n=5, mean ± SEM). (B) WT 
or Bcl6 cKO mice were immunized i.p. with 100 μg NP-KLH or 100 μg NP-KLH 
plus 5 mg AICAR. Blood serum were harvest on day 14 post immunization for NP-
KLH specific IgG ELISA analysis. The X-axis shows the dilution factors. Graphs 
show mean ± SEM, n = 3 (two-way ANOVA). *p < 0.05 (t test). Data are 
representative of two independent experiments with similar results.  
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AMPK regulates BCL6 and TFH markers in human T cells 
Since conditions for TFH cell differentiation have been more clearly 
characterized in human T cells compared to mice (93), we were curious if our 
findings with regulation of mouse Bcl6 by AMPK translated to human T cells. We 
therefore isolated naïve CD4 T cells from human peripheral blood mononuclear 
cells (PBMC), stimulated them in vitro with anti-CD3/anti-CD28 beads, and added 
reagents that modulate AMPK activity. We found that 2DG potently up-regulated 
both BCL6 and CXCR5 in human CD4 T cells (Fig. 11A, B). In fact, human T cells 
were extremely sensitive to 2DG compared to mouse cells, such that only 1.25 mM 
2DG was effective at increasing BCL6, whereas much higher concentrations of 
2DG were required to induce Bcl6 in mouse T cells (Fig. 5E). Nonetheless, this 
result indicated a similar regulatory pathway might exist for both mouse and human 
T cells. We then tested AICAR in the human CD4 T cell culture system. Similar to 
mouse T cells, AICAR was effective at significantly inducing BCL6 expression, 
both at the mRNA (Fig. 11C) and protein (Fig. 11E) level. Unlike with mouse T 
cells, AICAR induced significant up-regulation of the TFH markers CXCR5 (Fig. 
11D) and PD-1 (Fig. 11F). Strikingly, AICAR was more effective at inducing 
transcription of BCL6 (Fig. 11C) and CXCR5 (Fig. 11D) than when the CD4 T cells 
were cultured in characterized TFH cell conditions (93).  These data indicate that 
mouse and human T cells share a common AMPK pathway for inducing BCL6, 
however it also appears that human CD4 T cells are also more prone to develop 
into TFH–like cells than mouse CD4 T cells when this pathway is activated. 
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Figure 11: The AMPK pathway promotes TFH-like differentiation in human CD4 T 
cells. Human naïve CD4 T cells were treated with 2DG (A, B) or AICAR (C-F) at 
the concentrations indicated, in complete (GLU+) RPMI medium containing anti-
CD3/CD28 activation beads, cultured for 4 days. In (C, E), cells marked 
“Cytokines” were cultured with TFH skewing cytokines (IL-6, IL-12, TGFβ). (A, B, 
C, E) The expression levels of TFH genes (BCL6, CXCR5) were analyzed by 
QPCR, and normalized to the levels of GAPDH. (D, F) AICAR-treated cells were 
subjected to surface and intracellular staining with Abs to BCL6 and PD-1. Data 
are the normalized results from 3 individual T cell samples and preparations. 
Graphs show mean ± SEM, n = 3 (two-way ANOVA). *p < 0.05 (t test).  
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PART II: Bcl6 Promotes Follicular Helper T-cell Differentiation and PD-1 
Expression in a Blimp1-independent Manner in Mice. 
 
TFH cells but not TFR cells are dependent on Bcl6 for their development. 
The transcription factors Bcl6 and Blimp1 have opposing roles in the 
development of the follicular helper T (TFH) cells: Bcl6 promotes and Blimp1 
inhibits TFH‐cell differentiation. Similarly, Bcl6 activates, while Blimp1 represses, 
expression of the TFH‐cell marker PD‐1. However, Bcl6 and Blimp1 repress each 
other's expression, complicating the interpretation of the regulatory network. Here 
we sought to clarify the extent to which Bcl6 and Blimp1 independently control 
TFH‐cell differentiation by generating mice with T‐cell specific deletion of both Bcl6 
and Blimp1 (double conditional KO [dcKO] mice). Our results indicate that Bcl6 
promotes both TFH cell differentiation and PD‐1 expression by pathways 
essentially independent of Blimp1. 
 
 To analyze TFH cell differentiation when both Bcl6 and Blimp1 were deleted 
specifically in T cells, we generated CD4‐cre Bcl6fl/fl Prdm1fl/fl (dcKO) mice. These 
mice were healthy and T cell development was normal (data not shown). We 
immunized the mice with SRBC, and after 14 days, analyzed TFH cells in spleen 
(Fig. 12A and Fig. 13A). Control (Con) mice were Bcl6fl/fl Prdm1fl/fl without CD4‐
cre. Bcl6 cKO and Blimp1 cKO mice were also analyzed. Compared with Con, 
TFH cell populations were increased two‐fold in Blimp1 cKO mice, while TFH cells 
were completely absent in Bcl6 cKO and dcKO mice. These data indicate that Bcl6 
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is required for TFH cell development even in the absence of Blimp1‐mediated 
repression. Next, we analyzed the development of T follicular regulatory cells 
(TFR cells) (49, 50, 106, 109) after SRBC immunization (Fig. 12A and Fig. 13C, 
D). Blimp1 cKO mice have a sharply enhanced TFR cell population compared with 
Con mice, while TFR cells are nearly absent in Bcl6 cKO mice. However, TFR cells 
are significantly higher in dcKO mice than Bcl6 cKO mice, indicating that Blimp1 
represses TFR cells independent of Bcl6, and that TFR cells and TFH cells have 
somewhat different modes of development. We also analyzed GC B‐cells by flow 
cytometry in the same sets of mice (Fig. 12B and Fig. 13E, F), and GC B‐cell 
development paralleled TFH cell development in all four mouse lines. SRBC‐
specific IgG titers followed the levels of germinal center B (GCB) cells (Fig. 14). 
We analyzed TFH cells, TFR cells and GCB‐cells 7 days after SRBC 
immunization, and observed the same pattern as after 14 days (data not shown). 
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Figure 12: Gating strategies for TFH, TFR and germinal center B cells. Splenic 
single cell suspensions were admitted to flow cytometry machine, lymphocytes 
were first gated out using SSC and FSC. Then viable CD4+ T cells were gated and 
further gated as Foxp3+ or Foxp3- populations. TFH or TFR cells were gated from 
Foxp3- or Foxp3+ CD4+ T cells with CXCR5+PD-1+. GCB cells were gated using 
B220+ and GL7+CD38- markers.  
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Figure 13: Regulation of TFH cells, TFR cells and germinal center B cell by Bcl6 
and Blimp1. Control, Blimp1 cKO, Bcl6 cKO and dcKO mice were immunized with 
SRBC by i.p. injection. Fourteen days post‐immunization (dpi), spleens were 
isolated for flow cytometric analysis. TFH cells are defined as Foxp3−CXCR5hiPD‐
1hi. TFR cells are defined as Foxp3+CXCR5hiPD‐1hi. GC B cells are defined as 
B220+CD38loGL‐7hi. (A) Representative flow cytometry plots, gated on 
FoxP3– CD4+cells. (B) TFH‐cell percentage within Foxp3− CD4+ T cells and 
absolute TFH‐cell number per spleen. (C) Representative flow cytometry plots, 
gated on Foxp3+ cells. (D) TFR‐cell percentage in Foxp3+CD4+ T cells and 
absolute TFR‐cell number per spleen. (E) Representative flow cytometry plots. (F) 
GCB‐cell percentage in B220+ B cells and absolute GCB‐cell number per spleen. 
Flow cytometry plots are from a single experiment representative of 2 experiments 
with 16 total mice per experiment. Data in graphs are shown as mean ± SEM, n = 4 
with each symbol representing a single mouse. NS = not significant, p > 0.05, 
*p < 0.05 (two‐way ANOVA). Data are representative of 2 independent 
experiments with similar results with 16 total mice per experiment.  
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Figure 14: Antigen-specific IgG titers correlate with GC B cell responses. Control 
(Con), Blimp1 cKO, Bcl6 cKO and dcKO mice were immunized with SRBC by i.p. 
injection. At 14 dpi, blood serum samples were harvested for Ab analysis. (A) 
SRBC-specific total IgG, (B) SRBC-specific IgG1, (C) SRBC-specific IgG2b titers. 
X-axis shows the dilution factors. Graphs show mean ± SEM, n = 4 (two-way 
ANOVA). Data are representative of two independent experiments with similar 
results. 
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Bcl6 controls PD‐1 expression independent of Blimp1 
Bcl6 and Blimp1 have opposing roles in PD‐1 expression (104, 105), and 
we therefore analyzed PD‐1 expression in immunized Con, Bcl6 cKO, Blimp1 cKO 
and dcKO mice (Fig. 15). The average level of PD‐1 expression measured by MFI 
in total CD4 T cells showed very high PD‐1 in CD4 T cells from Blimp1 cKO mice 
(Fig. 15A and Fig. 16A), consistent with Blimp1 repressing PD‐1 expression. Since 
PD‐1 expression in dcKO CD4 T cells is much lower than in Blimp1 cKO CD4 T 
cells, this indicates a positive role for Bcl6 in PD‐1 regulation. Since the PD‐1 levels 
on total CD4 T cells are skewed by the presence of PD‐1high expressing TFH cells, 
we analyzed PD‐1 expression on PD‐1+ non‐TFH cells (Fig. 15B and Fig. 16B). 
Loss of Blimp1 again increased PD‐1 in non‐TFH cells, whereas PD‐1 in Bcl6 cKO 
and dcKO non‐TFH cells was similar as control (Con) levels. These data indicate 
that the higher PD‐1 in Blimp1 cKO non‐TFH cells requires Bcl6 expression, but 
did not answer whether Bcl6 could regulate PD‐1 independently of Blimp1. To 
address this question, we used retroviruses (RVs) to express Bcl6 in activated CD4 
control and dcKO T cells, then assessed PD‐1 expression. As shown in Fig. 15C 
and Fig. 16C, Bcl6 significantly augmented PD‐1 expression as measured by MFI, 
in both control and dcKO T cells, showing clearly that Bcl6 could activate PD‐1 
expression independent of Blimp1. Indeed, Bcl6 induced higher expression of 
the Pdcd1 gene (Fig. 17A), whereas a known Bcl6 target, Il10 (80, 101) was 
strongly repressed by Bcl6 RV (Fig. 17B). Thus, Bcl6 can both activate and repress 
gene expression, independently of Blimp1. Since Blimp1 has been shown to 
positively regulate IL‐10 (192), our data also rules out a mechanism of IL‐10 control 
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where Bcl6 acts on IL‐10 by repressing Blimp1 and causing 
decreased Il10 transcription, and shows that Bcl6 is a direct repressor 
of Il10 expression. 
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Figure 15: Control of PD‐1 expression by Bcl6 and Blimp1. Control, Blimp1 cKO, 
Bcl6 cKO and dcKO mice were immunized with SRBC by i.p. injection. At 14 days 
dpi, spleens were isolated for flow cytometric analysis. (A) PD‐1 MFI of total 
CD4+ T cells at 14 dpi (n = 4, mean ± SEM). (B) PD‐1 MFIs of 
CD44+ CXCR5− PD‐1+ non‐TFH cells. (C) Control and dcKO CD4+ T cells were 
infected with Bcl6‐expressing and control retroviruses (RVs). **p < 0.01 (two‐way 
ANOVA). Each symbol in graphs represents one mouse. Data are representative 
of 2 independent experiments with similar results with 16 total mice per 
experiment.  
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Figure 16: Control of PD-1 expression by Bcl6 and Blimp1 (2). Control, Blimp1 
cKO, Bcl6 cKO and dcKO mice were immunized with SRBC by i.p. injection. At 14 
days dpi, spleens were isolated for flow cytometric analysis. (A) histogram plot 
showing representative PD-1 expression and (B) PD-1 MFIs of CD44+ CXCR5- 
PD-1+ non-TFH cells at 14 dpi (n=7, mean ± SEM). (C) PD-1 MFIs of control and 
dcKO CD4+ T cells infected with Bcl6‐expressing and control RVs. All color codes 
correspond to Figure 15. **p < 0.01, ***p < 0.001 (two-way ANOVA). Each symbol 
in graphs represents one mouse. Data are representative of two independent 
experiments with similar results. 
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Figure 17: Bcl6 regulates IL-10 and PD-1 independent of Blimp1. Control and 
dcKO CD4+ T cells were infected with Bcl6-expressing and control retroviruses 
(RVs). (A) Relative mRNA expression was determined by quantitative RT-PCR. 
Pdcd1 gene expression from isolated dcKO-ConRV and dcKO-Bcl6RV infected 
cells (n=3, mean ± SEM). (B) IL-10 (Il10) gene expression from isolated dcKO-
ConRV and dcKO-Bcl6RV infected cells after 5 hours of re-stimulation in anti-CD3 
and anti-CD28 coated wells (n=3, mean ± SEM). **p < 0.01 ***p < 0.001 (t test).   
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A T‐bet‐dependent mechanism for the activation of PD‐1 expression by 
Bcl6 
We next sought to find the mechanism for how Bcl6, a transcriptional 
repressor, could promote Pdcd1 mRNA expression independent of Blimp1. One 
explanation is that Bcl6 represses the transcription of microRNAs that silence PD‐
1 expression (193). We therefore tested the role of microRNAs in the induction of 
PD‐1 by Bcl6, and found that Bcl6 RV could still up‐regulates PD‐1 in Dicer cKO T 
cells, which are unable to generate microRNAs (Fig. 18). We then sought other 
pathways. T‐bet is a transcriptional repressor of PD‐1 gene expression (194), and 
Bcl6 is a negative regulator of T‐bet (195). Therefore, we wondered if a T‐bet‐Bcl6 
pathway could play a role in PD‐1 expression in CD4 T cells. We tested this idea 
by transducing primary mouse CD4 T cells with T‐bet‐expressing RV, with and 
without Bcl6 RV. As shown in Fig. 19A, T‐bet RV can significantly repress PD‐1 
expression compared with control RV, whereas addition of Bcl6 RV allows for PD‐
1 activation even in the presence of T‐bet RV. To further investigate this pathway, 
we analyzed PD‐1 expression in Tbx21−/− (Tbx21 KO or T‐bet‐deficient) CD4 T 
cells and as expected, we saw higher PD‐1 in T‐bet KO T cells compared with wild‐
type T cells (Fig. 19B). Notably, Bcl6 RV was able to strongly activate PD‐1 
expression in wild‐type T cells (∼50% increase in MFI) but Bcl6 RV was only able 
to activate PD‐1 relatively weakly in T‐bet KO T cells (∼20% increase in MFI) 
(Fig. 19B and C). These data indicate that a major pathway for the up‐regulation 
of PD‐1 expression by Bcl6 is by counteracting the repressive action of T‐bet on 
PD‐1 expression.  
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Figure 18: BCL6 can augment CXCR4, CXCR5 and PD-1 expression in the 
absence of microRNA. Naïve CD4 T cells were taken from wild-type and CD4-cre 
dicer-fl/fl mice, activated with CD3/CD28 Abs then infected with GFP control or 
GFP/BCL6-expressing retrovirus. After 2 days in culture, cells were stained for 
CXCR4, CXCR5 and PD-1 and expression in GFP+ cells analyzed by flow 
cytometry. Graph shows the % increase in expression induced by BCL6 in either 
wild-type or dicer KO T cells, as well as the general increase in expression in wild-
type T cells versus dicer KO T cells. Data from 4 separate experiments was 
averaged for the graph. (Data generated by Hao Wu). 
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Figure 19: Control of PD‐1 expression by Bcl6 and Tbet. Total CD4+ T cells from 
wild‐type (WT) or Tbx21 cKO mice were co‐infected with Bcl6‐H2Kk‐expressing 
and T‐bet‐GFP‐expressing and control RVs. PE‐labeled anti‐H2Kk Ab was used to 
detect H2Kk expressing cells. Double GFP+PE+ cells were gated on for analysis. 
(A) PD‐1 MFI of total CD4+ T cells from WT mice after control, Bcl6, T‐bet or Bcl6 
plus T‐bet RV co‐infection (n = 4, mean ± SEM). (B) PD‐1 MFI of total CD4+ T cells 
after control, Bcl6, T‐bet or Bcl6 plus T‐bet RV co‐infection. Statistical 
designations: * compares WT to Tbx21 KO, # compares WT with the different RV 
infections, @compares Tbx21 KO with the different RV infections. (C) Percentage 
of increase of PD‐1 MFI of total CD4+ T cells after control or Bcl6 RV infection in 
same experiment as (B). ***, @@@, ### = p < 0.001, ** = p < 0.01 (t‐test). Data are 
representative of two independent experiments with similar results, and with four 
mice per condition per experiment.  
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In summary, we have clarified several aspects of Bcl6 control over TFH cell 
and TFR cell differentiation (see model in Fig. 20). Specifically, we have found that: 
(i) Blimp1 primarily represses TFH cell differentiation by acting on Bcl6, (ii) Blimp1 
represses TFR cell differentiation through both Bcl6‐dependent and Bcl6‐
independent pathways and (iii) Bcl6 promotes PD‐1 expression by a novel Blimp1‐
independent mechanism involving T‐bet inhibition. 
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Figure 20: Models for regulation of TFH cells, TFR cells and PD-1 by Bcl6, Blimp1 
and Tbet. (A) Regulation of TFH cells by Bcl6 and Blimp1, (B) Regulation of TFR 
cells by Bcl6 and Blimp1, (C) Regulation of PD-1 by Bcl6 and Tbet. Arrow = positive 
regulation, T-end line = negative regulation, dotted line = indirect regulation.   
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PART III: Follicular Regulatory T Cells are Necessary for and Promote 
Antigen-Specific IgE Production in a Food Allergy Model. 
 
TFR cells have been shown to suppress the proliferation of TFH cells and 
GC B cells, and can also facilitate the selection of high affinity B cell clones in the 
GC. Here, we used a peanut Ag food allergy model in mice to examine the role of 
TFR cells in controlling the production of Ag-specific IgE and IgE-mediated 
anaphylaxis. 
 
Production of antigen-specific IgE in a food allergy model is dependent upon 
both TFR cells and the GC reaction.  
To study the role of TFR cells in regulating IgE production and IgE 
responses, we used our Bcl6FC mouse model, in which TFR cells do not develop 
(109), and a widely-used model of food allergy induced by i.g. challenge of peanut 
protein plus cholera toxin (PCT)(Fig. 21A)(177). In this food allergy model, high 
levels of peanut-specific IgE are induced and maintained in circulation for weeks. 
As shown in Fig. 21B, 4 weeks after the challenge period, WT mice produced 
substantial levels of peanut-specific IgE. Our initial expectation was that IgE would 
be produced at higher levels in the absence of TFR cells, however we found that 
the IgE response was essentially lost in Bcl6FC mice after 4 weeks (Fig. 21B). 
Peanut-specific IgG1 was significantly decreased in the Bcl6FC mice but was 
easily detectable (Fig. 21B). We then analyzed the time course of serum peanut-
specific IgE and IgG1 induction and maintenance in the PCT model (Fig. 21C, D). 
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We observed that peanut-specific IgE was induced to high levels one week after 
the second PCT challenge and then slowly decreases over several weeks, 
whereas in Bcl6FC mice, the initial induction of IgE is severely blunted and then 
fades to undetectable levels at two weeks after PCT challenge. In contrast, peanut-
specific IgG1 was strongly induced and maintained at high levels for weeks after 
the PCT challenge in both WT and Bcl6FC mice, even though the levels were 
significantly lower in the TFR-deficient Bcl6FC mice. To assess the physiological 
relevance of peanut-specific IgE levels at day 36, we induced anaphylaxis by i.p. 
injection of peanut protein alone (Fig. 21E). A strong anaphylaxis response was 
induced in PCT challenged WT mice, while anaphylaxis was dramatically weaker 
in Bcl6FC mice.  We then tested if the induction of peanut-specific IgE was 
dependent on the GC reaction by performing PCT challenge of CD4-cre Bcl6-flox 
mice which lack TFH and GCB cells (103). We observed that the anti-peanut IgE 
response was completely ablated in these mice although some anti-peanut IgG1 
was still produced (Fig. 21F). Similar results on GC dependence were observed 
when we tested Mb1-cre Bcl6-flox mice by PCT challenge (Fig. 22 A, B). CD4-cre 
Bcl6-flox mice showed no signs of anaphylaxis when challenged i.p. with peanut 
protein (Fig. 21G), confirming the IgE dependence of the anaphylaxis and showing 
the strict dependence of Ag-specific IgE responses on the GC reaction. Similar 
results showing Ag-specific IgE dependence on GC responses and TFR cells were 
observed when Ovalbumin was substituted for peanut protein in the food allergy 
model (Fig. 22 C, D), showing that these results were not unique to peanut as an 
Ag. Overall these data indicate that in this food allergy model, the development of 
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peanut-specific IgE requires the GC reaction and that TFR cells play a helper 
rather than a suppressor role in IgE responses. Our data also imply that TFR cells 
act within the GC to regulate IgE. 
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Figure 21: Lack of TFR cells in a food allergy model leads to loss of antigen-specific 
IgE and decreased anaphylaxis responses. 
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Figure 21: Lack of TFR cells in a food allergy model leads to loss of antigen-specific 
IgE and decreased anaphylaxis responses. The food allergy model uses two i.g. 
challenges in mice of peanut protein plus cholera toxin (PCT) 7 days apart, then 
bleeds at different time-points after challenge. (A) shows the day 36 (D36) time-
course, where serum is tested 28 days after the last challenge for peanut-specific 
Abs. (B-D) Control Foxp3-cre alone (WT) mice and Foxp3-cre Bcl6-flox (Bcl6FC) 
mice were challenged as shown in (A) and D36 serum was tested for peanut-
specific IgE and IgG1 (B) or at various time-points during and after challenge (C-
D). (E) WT and Bcl6FC mice challenged as in (A) were analyzed for anaphylactic 
responses at D36. Naïve unchallenged WT and Bcl6FC mice were used as 
negative controls. For induction of anaphylaxis, female mice were injected i.p. with 
2 mg of peanut protein at D36, then monitored for drop in body temperature 
(hypothermia) over the course of 50 minutes (min). Clinical signs were assessed 
20 to 30 min after injection. After 50 min, blood was taken from the mice and 
percent hematocrit (hemoconcentration) tested. (F-G) Control Bcl6fl/fl alone (WT) 
mice and CD4-cre Bcl6-flox (CD4-Bcl6 cKO) mice were challenged as shown in 
(A). (F) D36 serum was tested for peanut-specific IgE and IgG1. (G) Female mice 
were tested for anaphylaxis as described in (E). Naïve unchallenged WT and CD4-
Bcl6 cKO mice were used as negative controls. P values were calculated by t test 
or ANOVA where * p < 0.05, ** p < 0.01, *** p < 0.0001. N = 4 - 6 mice, and each 
experiment was repeated at least 2 or 3 times. 
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Figure 22: Block of GC B cell development leads to loss of TFH, TFR cells and 
peanut-specific IgE.  
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Figure 22: Block of GC B cell development leads to loss of TFH, TFR cells and 
peanut-specific IgE. (A) WT and Mb1-cre Bcl6-flox (MB1-Bcl6-/-) mice were 
challenged as in Figure 21 with PCT then at D36, mesenteric lymph nodes (LN) 
and spleens (SP) analyzed for the indicated cell populations by flow cytometry. 
Graphs show average % of cells as a fraction of parental cell population and total 
yield of cells. GCB, TFH and TFR cells analyzed as in Figure 22. (B) Peanut-
specific IgE and IgG1 titers from D36 serum of WT and MB1-Bcl6-/- mice 
challenged with PCT. (C) Ova-specific IgE and IgG1 titers from D36 serum of WT 
and Bcl6FC mice challenged twice with Ovalbumin + cholera toxin. (D) Ova-
specific IgE and IgG1 titers from D36 serum of WT and CD4-Bcl6cKO mice 
challenged twice with Ovalbumin + cholera toxin.  
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TFR cells are required to maintain GC responses over time 
We wondered if loss of Ag-specific IgE represented a loss of IgE switching 
in B cells in the GCs of Bcl6FC mice. However, we did not observe a significant 
difference in the percentage of IgE+ GCB cells between WT and Bcl6FC mice (Fig. 
23A). We then examined cells of the GC response to see if there was a defect in 
the GC reaction itself. As expected, TFR cells were almost completely absent in 
Bcl6FC mice despite a robust TFR response in WT mice with PCT challenge (Fig. 
24A). Surprisingly, we observed a significant decrease in TFH cells in Bcl6FC mice 
after PCT challenge (Fig. 24B) and an even larger loss of GCB cells (~70% 
decrease) in Bcl6FC mice after PCT challenge (Fig. 24C). We examined the time 
course of the GC response and saw in WT mice, TFR, TFH and GCB cells all 
increased over time and remained high 4 weeks after the last challenge (D36; Fig. 
24D). The TFH and GCB cell responses looked basically normal at the early stages 
in Bcl6FC mice, but, decreased at later stages of the analysis. In particular, there 
was a sharp decrease in GCB cells at day 36 of the response. GCB cells from WT 
mice continued to expand up to day 36 but in Bcl6FC mice lacking TFR cells, GCB 
cell growth leveled off at day 15. We confirmed these trends in a more robust PCT 
priming model involving 8 total PCT challenges, showing that TFR cells were still 
required even in a response with near saturating Ag (Fig. 23 B-D). These data 
indicate that in the PCT food allergy model, TFR cells are required to promote 
and/or maintain GC growth.  
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Figure 23: TFR cells are required for normal GC responses and IgE levels after 8 
challenge food allergy priming.   
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Figure 23: TFR cells are required for normal GC responses and IgE levels after 8 
challenge food allergy priming. (A) IgE+GCB cells in WT and Bcl6FC mice as a % 
of total GCB cells. (B) This food allergy priming uses 8 i.g. challenges of PCT, each 
7 days apart, then bleeds at different time-points after challenge. shows the day 
36 (D36) time-course, where immune cells and serum tested 43 days after the last 
challenge. Peanut-specific IgE and IgG1 titers from D92 serum of WT and Bcl6FC 
mice challenged 8 times with PCT. (C) WT and Mb1-cre Bcl6-flox (MB1-Bcl6-/-) 
mice were challenged as in part (A) with PCT then at D92, mesenteric lymph nodes 
(LN) and spleens (SP) analyzed for the indicated cell populations by flow 
cytometry. Graphs show average % of cells as a fraction of parental cell population 
and total yield of cells. GCB, TFH and TFR cells analyzed as in Figure 22. (D) 
Time-course of the TFR, TFH and GCB response after 8 PCT challenges. D15 = 
7 days after challenge, D56 = 7 days after last challenge, D92 = 43 days after last 
challenge.  
  
90 
 
Figure 24: TFR cells are required for normal TFH and GC B cell numbers in a food 
allergy immune response.  
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Figure 24: TFR cells are required for normal TFH and GC B cell numbers in a food 
allergy immune response. WT and Bcl6FC mice were challenged as in Figure 21 
with PCT then at D36, mesenteric lymph nodes (LN) and spleens (SP) analyzed 
for the indicated cell populations by flow cytometry. Representative contour dot 
plots for each cell staining are shown along with graphs showing average % of 
cells as a fraction of parental cell population and total yield of cells.  (A) Analysis 
of CD4+Foxp3+PD-1+CXCR5+ TFR cells. TFR cells are quantitated as a 
percentage of Foxp3+CD4+ T cells, and absolute number per LN or SP. (B) 
Analysis of CD4+Foxp3- PD-1+CXCR5+ TFH cells. TFH cells are quantitated as 
a percentage of Foxp3- CD4+ T cells, and absolute number per LN or SP.  (C) 
Analysis of B220+CD38- GL7+ GCB cells. GCB cells are quantitated as a 
percentage of B220+ cells, and absolute number per LN or SP. (D) Time-course 
of the TFR, TFH and GCB responses after PCT challenges. D15 = 7 days after 
challenge, D22 = 14 days after challenge, D36 = 28 days after challenge. P values 
were calculated by t test where * p < 0.05, ** p < 0.01, *** p < 0.0001. N = 4 - 6 
mice, and each experiment was repeated 2 to 8 times. 
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Treg cells are required for antigen-specific IgE production in the food allergy 
model 
We next wondered whether our results with Bcl6FC mice were unique to 
this mouse model of TFR deficiency. We therefore obtained Foxp3-diptheria toxin 
receptor (Foxp3-DTR) mice where Foxp3+ Treg cells can be depleted by injection 
of diphtheria toxin (DT), causing loss of TFR cells (49, 137), and tested them in the 
PCT model as shown in Fig. 25A. Similar to our results with Bcl6FC mice, deletion 
of total Tregs led to a dramatic loss of peanut-specific IgE and a significant but not 
complete loss in peanut-specific IgG1 (Fig. 25B). We then confirmed that the DT 
treatment led to essentially complete deletion of Tregs at an early stage of the 
response in the Foxp3-DTR mice (Fig. 25C, D). These data support the idea that 
TFR cells are required for producing Ag-specific IgE. 
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Figure 25: Total Treg and TFR cells are required for antigen-specific IgE and IgG1 
in a food allergy response.  
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Figure. 25. Total Treg and TFR cells are required for antigen-specific IgE and IgG1 
in a food allergy response. (A) Foxp3-DTR mice were treated with diphtheria toxin 
(DT) as indicated to deplete Treg cells, or given PBS as a control, challenged with 
PCT as indicated, and bled for serum peanut-specific IgE and IgG1 Ab on D36 (B). 
(C) Foxp3-DTR mice were treated with DT or given PBS as a control, challenged 
with PCT at days 0 and 7 as indicated, and then at day 9, draining mesenteric 
lymph node (LN) and spleen (SP) taken for analysis of Foxp3+ Treg cells by flow 
cytometry (D). Representative contour dot plots for Treg staining are shown along 
with graphs showing average % of Treg cells as a fraction of CD4 T cells and total 
yield of Treg cells. P values were calculated by t test or ANOVA where * p < 0.05, 
** p < 0.01, *** p < 0.0001. N = 5 - 8 mice, and each experiment was repeated 2 
times. 
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TFR cells actively promote antigen-specific IgE 
Although our experiments showed that TFR cells were necessary for 
peanut-specific IgE responses in the PCT model, our data did not indicate if TFR 
cells were simply required at some minimal level in the GC response or if TFR cells 
actively promoted peanut-specific GCB cell responses. We therefore used a 
mouse line previously shown to develop augmented TFR responses due to a 
specific deletion of Pten expression in Treg cells (Foxp3-cre Pten-flox or PtenFC 
mice (174)) to test this hypothesis. We challenged PtenFC mice with PCT and 
analyzed the resulting immune response. As shown in Fig. 26A, peanut-specific 
IgE was strongly increased in PtenFC mice compared to WT mice, while peanut-
specific IgG1 production was not affected. We confirmed TFR cells were 
significantly augmented in the PCT-challenged PtenFC mice (Fig. 26B), and 
observed that this increase was associated with an increase in both TFH and GCB 
cells (26C, D; Fig. 27). These data challenge the notion that TFR cells act as 
suppressors of the GC response, as is typically proposed for TFR function. Instead 
our data show that TFR cells crucially drive GC responses in this food allergy 
model, and this idea is supported by a linear correlation analysis between numbers 
of TFR cells and other cells in the GC (Fig. 26E). As expected, numbers of TFH 
and GCB cells were tightly correlated, but TFR cells also positively correlated with 
both GCB and TFH cells. This finding, coupled with the weak GCB cell response 
in Bcl6FC mice suggests that TFR cells are active helper cells of the Ab response 
in the PCT food allergy model. 
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Figure 26: Augmented TFR cell development promotes higher IgE and correlates 
with increased GC responses after food allergy challenge.   
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Figure 26: Augmented TFR cell development promotes higher IgE and correlates 
with increased GC responses after food allergy challenge. WT and Foxp3-cre 
Pten-flox (PtenFC) mice were challenged as in Figure 21 with PCT.  At D36 of the 
challenge system, (A) serum was tested for peanut-specific Abs, and (B-D) 
spleens (SP) were analyzed for TFR cells, TFH cells and GCB cells by flow 
cytometry as in Figure 22. Representative contour dot plots for each cell staining 
are shown along with graphs showing average % of cells as a fraction of parental 
cell population and total yield of cells.  (E) Linear correlation analysis between TFH 
cell % and GCB cell %, between TFR cell % and GCB cell % and between TFR 
cell % and TFH cell %, using data combined from WT and PtenFC mice. P values 
were calculated by t test or ANOVA where * p < 0.05, ** p < 0.01, *** p < 0.0001. 
R square values in (E) were calculated by Prism GraphPad software. N = 4 mice. 
Each experiment was repeated 2 times. 
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Figure 27: Augmented TFR, TFH and GC B cells responses in the lymph node of 
Pten conditional knockout mice after food challenge. WT and Foxp3-cre Pten-flox 
(PtenFC) mice were challenged as in Figure 21 with PCT.  At D36 of the challenge 
system, LN were analyzed for TFR cells, TFH cells and GCB cells by flow 
cytometry as in Figure 22. Representative contour dot plots for each cell staining 
are shown along with graphs showing average % of cells as a fraction of parental 
cell population and total yield of cells. P values were calculated by t test where * p 
< 0.05, ** p < 0.01, *** p < 0.0001. R square values in (E) were calculated by Prism 
GraphPad software. N = 4 mice. Each experiment was repeated 2 times. 
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Blimp1-controlled IL-10 is key for IgE responses 
We next tested TFR cell function in the PCT food allergy model using 
Blimp1FC mice, where Blimp1 is specifically deleted in Tregs cells by Foxp3-cre. 
Since Blimp1 is an antagonistic transcriptional regulator of the follicular T cell 
differentiation and Blimp1 represses the master follicular T cell transcription factor 
Bcl6 (51, 82), Blimp1FC mice are predicted to have an augmented TFR cell 
response, due to higher Bcl6 expression. Indeed, we found markedly increased 
TFR cells in Blimp1FC mice when are challenged with PCT (Fig. 28A), and 
consistent with our other findings in this model, TFH and GCB cells were also 
elevated (Fig. 28 B, C). However, when we tested for peanut-specific IgE and 
IgG1, the levels made by Blimp1FC mice were comparable to WT levels (Fig. 28D). 
These results show that the increased TFR cells in Blimp1FC mice did not boost 
Ab production, which contrasts to what we saw with PtenFC mice with increased 
TFR cells. Since Blimp1 is known to positively control IL-10 expression in Treg 
cells (196-198), and TFR cells produce IL-10 that helps promote GC responses 
(68), we wondered if loss of IL-10 production from Blimp1-deficient TFR cells was 
causing the lack of IgE increase after PCT challenge. We used ELISA to test IL-
10 expression and found about a 6-fold decrease in IL-10 secretion from Blimp1FC 
Tregs (Fig. 28E). To test if other Treg or TFR cell genes were altered in Blimp1FC 
TFR cells besides IL-10, we used RNAseq to profile gene expression in FACS 
sorted TFR cells from WT and Blimp1FC mice. Overall, 198 (1.6%) of the 
sequenced genes were differentially expressed between WT and Blimp1FC TFR 
cells (data not shown). When we analyzed a panel of key Treg and TFR genes 
100 
profiled by RNAseq, we saw that only IL-10 was strongly affected by loss of Blimp1, 
with a 7-fold decrease in Il10 RNA (Fig. 28F). These data indicate that even though 
TFR cells are produced at higher levels in Blimp1FC mice, they are defective at 
promoting higher peanut-specific IgE in the PCT model, likely because of a 
deficiency in IL-10 production. 
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Figure 28: Blimp1-dependent IL-10 produced by TFR cells helps promote IgE 
responses in food allergy. 
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Figure 28: Blimp1-dependent IL-10 produced by TFR cells helps promote IgE 
responses in food allergy. (A-D) WT, Bcl6FC and Foxp3-cre Blimp1-flox 
(Blimp1FC) mice were challenged as in Figure 21 with PCT. At D36 of the 
challenge system, spleens (SP) were analyzed by flow cytometry as in Figure 22 
for (A) TFR cells, (B) TFH cells, (C) GCB cells, and (D) serum was tested for 
peanut-specific Abs. Representative contour dot plots for each cell staining are 
shown along with graphs showing average % of cells as a fraction of parental cell 
population and total yield of cells.  (E) IL-10 ELISA data for 72 hr supernatants 
from CD3+CD28 stimulated Tregs from WT, Bcl6FC and Blimp1FC mice. P values 
were calculated by t test or ANOVA where * p < 0.05, ** p < 0.01, *** p < 0.0001. 
N = 5 mice, and each experiment was repeated 2 times. (F) Heat map showing 
RNA transcript levels of key follicular T cell and Treg cell genes in TFR cells from 
WT and Blimp1FC mice. Transcript levels were determined by RNAseq. TFR cells 
were isolated by FACS from PCT challenged mice (N= 4 of each strain). Color 
scale representing absolute RNA levels is shown on the right as Log2RPKM 
values.   
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IL-10 is critical for antigen-specific IgE responses  
To further clarify the role of IL-10 in regulating peanut-specific IgE in our 
food allergy model, we used Mb1-cre IL-10Ra-flox (MB1-Il10ra-/-) mice, where the 
IL-10 receptor alpha gene is deleted specifically in B cells and thus the B cells 
cannot respond to IL-10 signals. These mice were challenged with PCT and tested 
for GC and peanut-specific Ab responses. As shown in Fig. 29A-B, loss of IL-10 
signaling in B cells led to significantly decreased GCB cell responses and a 
complete loss of peanut-specific IgE, while leaving the peanut-specific IgG1 
response intact. We also tested germline IL-10-/- mice with PCT challenge and 
found significant decreases in peanut-specific IgE and IgG1 (Fig. 29C), again 
supporting a key role for IL-10 in controlling the IgE response to a food allergen.  
We then wondered if we could block IgE production in WT mice with anti-IL-10R 
Ab after PCT challenge, an approach with therapeutic potential. As shown in Fig. 
29D-E, repeated doses of anti-IL10R Ab in WT mice after PCT challenge led to a 
dramatic loss of peanut-specific IgE by day 29 with only a small drop in peanut-
specific IgG1 at day 29. Significantly, anti-IL10R Ab treatment also strongly 
inhibited anaphylaxis after peanut challenge (Fig. 29F), mirroring the loss of IgE 
production. We also tested the role of IL-10 signaling on CD4 T cells with CD4-cre 
IL10Ra-flox mice and the PCT challenge system, however there was little 
difference in anti-peanut IgE and IgG1 and the GC response in these mice (Fig. 
30). These data support the idea that IL-10 acts on GCB cells to promote the IgE 
response. To further investigate the effect of IL-10 acting on GCB cells, we 
examined the light zone and dark zone composition of GCB cells in MB1-Il10ra-/- 
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mice, and found a large shift to light zone GCB cells in these mice (Fig. 31A). 
These data are consistent with recent findings that IL-10 promotes entry of the 
GCB cell into the dark zone compartment of the GZ (68), and thus without IL-10 
signaling, GCB cells tend to accumulate in the light zone. We further found an 
extreme shift of GC B cells to the light zone in Bcl6FC mice (Fig. 31B), which is 
consistent with a loss of TFR cell derived IL-10 in Bcl6FC mice. Lastly, we 
observed a 2-3 folds increase in dead GCB cells in Bcl6FC mice (Fig. 31C), which 
is likely related to loss of IL-10 signaling and can explain the loss of GCB cells in 
these mice. 
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Figure 29: IL-10 promotes GC B cell levels and peanut-specific IgE, and 
therapeutic blockade of IL-10 during food allergy challenge leads to loss of IgE. 
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Figure 29: IL-10 promotes GC B cell levels and peanut-specific IgE, and 
therapeutic blockade of IL-10 during food allergy challenge leads to loss of IgE. 
(A) WT and Mb1-cre IL-10Ra-flox (MB1-Il10ra-/-) mice were challenged with PCT 
and at D36, and GCB cells from LN and SP were stained and analyzed by flow 
cytometry. Representative contour dot plots of GCB cell staining are shown along 
with graphs showing average % of GCB cells and total yield of cells. (B) Peanut-
specific IgE and IgG1 titers from D36 serum of WT and MB1-Il10ra-/- mice 
challenged with PCT. (C) Peanut-specific IgE and IgG1 levels from D36 serum of 
WT and Il10-/- (IL-10 KO) mice challenged with PCT. (D) Scheme for block of IL-
10 receptor during PCT challenge in female C57Bl/6 WT mice. Numbers indicate 
specific days for i.p. anti-IL10R Ab treatment, i.g. PCT gavage, blood sampling and 
anaphylaxis. Control mice received anti-HRP-IgG1 Ab. (E) Peanut-specific IgE and 
IgG1 titers from serum of control and anti-IL10R mice treated as described in (D) 
at the indicated timepoints. (F) Anaphylaxis response of control and anti-IL10R 
mice treated as described in (D). Anaphylaxis analysis was performed as in Figure 
21. P values were calculated by t test or ANOVA where * p < 0.05, ** p < 0.01, *** 
p < 0.0001. N = 4 - 6 mice, and each experiment was repeated 2 times. 
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Figure 30: IL-10 signaling on T cells does not affect food allergy GC response and 
IgE production. 
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Figure 30: IL-10 signaling on T cells does not affect food allergy GC response and 
IgE production. (A) WT and CD4-cre IL10ra-flox (CD4-Il10ra-/-) mice were 
challenged as in Figure 21 with PCT.  At D36 of the challenge system, SP were 
analyzed for TFR cells, TFH cells and GCB cells by flow cytometry as in Figure 22. 
Graphs show average % of cells as a fraction of parental cell population and total 
yield of cells. (B) Peanut-specific IgE and IgG1 titers from D36 serum of WT and 
CD4-Il10ra-/- mice challenged with PCT. P values were calculated by t test or 
ANOVA where * p < 0.05, ** p < 0.01, *** p < 0.0001. N = 6 mice. Each experiment 
was repeated 2 times. 
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Figure 31: Altered GCB cell cycling and increased apoptosis in the absence of TFR 
cells. (A) WT and Mb1-cre IL-10Ra-flox (MB1-Il10ra-/-) mice were challenged with 
PCT and at D36, and GCB cells from SP were stained and analyzed by flow 
cytometry for light zone (LZ; CXCR4) and dark zone (DZ; CD86) marker 
expression. Representative contour dot plots of GCB DZ/LZ cell staining are 
shown along with graphs showing average ratios of GCB LZ to GCB DZ cells. (B) 
WT and Bcl6FC mice were challenged with PCT and at D36, and GCB cells from 
SP were stained and analyzed by flow cytometry for LZ and DZ marker expression 
as in part A. Representative contour dot plots of GCB DZ/LZ cell staining are 
shown along with graphs showing average ratios of GCB LZ to GCB DZ cells. (C) 
WT and Bcl6FC mice were challenged with PCT and at D36, and GCB cells from 
SP were stained and analyzed by flow cytometry for viability using eBioscience™ 
Fixable Viability Dye. Representative viability stains are shown along with graphs 
showing average GCB cell death. P values were calculated by t test where * p < 
0.05, ** p < 0.01, *** p < 0.0001. N = 4 - 5 mice, and each experiment was repeated 
2 times. 
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PART IV: Follicular Regulatory T Cells Inhibit the Development of Aberrant 
Granzyme B Expressing Follicular Helper T Cells. 
 
T follicular regulatory (TFR) cells can have both suppressive and helper 
roles in the germinal center (GC). Using a peanut food allergy model, we found 
GC B cells and peanut-specific IgE were significantly decreased in TFR-deficient 
mice, whereas T follicular helper (TFH) cell number was not affected. Using gene 
profiling, we found that TFH cells from TFR-deficient mice showed strong up-
regulation of granzyme B (Gzmb) and other effector CD8 T cell genes. This 
aberrant cytotoxic T cell gene profile was strongly associated with Stat4 activity 
but was not associated with a canonical Th1 profile. We detected Gzmb+ and 
Eomesodermin+ TFH cells and a higher rate of apoptotic GC B cells in the absence 
of TFR cells. Our data show that TFR cells can positively regulate the GC response 
by repressing abnormal TFH cell differentiation, which leads to increased GC B 
cell numbers and increased Ag-specific Ab.  
 
TFR cells promote stronger GC B cell and IgE responses  
To study Ag-specific Ab responses, we used a classic model of food allergy 
induced by i.g. challenge with PCT (177, 180, 199). In this model, high levels of 
peanut-specific IgE are induced and maintained in circulation for weeks after 
immunization in normal mice. To test the role of TFR cells, we used the Bcl6FC 
TFR cell-deficient mouse model (109), mice where Blimp1 was deleted in Foxp3+ 
cells (Blimp1FC) leading to higher TFR cells and mice with deletion of both Bcl6 
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and Blimp1 in Foxp3+ cells (DKO). All mouse strains were healthy with no obvious 
disease by week 6-10. As shown in Fig. 32A, TFR cells were largely ablated in 
Bcl6FC and DKO mice but were increased about 2-fold over WT levels in 
Blimp1FC mice. These data show dominant role for Bcl6 in TFR cell development. 
Loss of TFR cells did not affect TFH cell numbers, however there was a marked 
increase in both Blimp1FC and DKO TFH cells (Fig. 32B). Blimp1 is required for 
IL-10 expression by regulatory T cells (Tregs; (200, 201)). TFR cell levels strongly 
affected GCB cell levels, showing a strong positive correlation in Bcl6FC, 
Blimp1FC and DKO strains (Fig. 32C, Fig. 33). These data show that TFR cells 
play a helper role for GCB cell responses. Indeed, we observed a 5-6 folds lower 
GC B cells to TFH cells in TFR cell deficient mice compared to TFR sufficient mice, 
indicating the TFH cells are less efficient helpers in the absence of TFR cells (Fig. 
32 D, E). Analysis of peanut-specific IgE titers revealed that TFR cells are required 
for sustained IgE responses in this model (Fig. 32F). Overall, these findings 
support the idea that TFR cells positively regulate the GC B cell population and the 
IgE response. 
 
TFR cells inhibit the development of aberrant cytotoxic gene expressing TFH 
cells 
To better understand how TFR cells were influencing the ability of TFH cells 
to help GCB cells in our model, we used RNAseq to profile gene expression in  
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Figure 32: TFR cells are required for proper GC B cell numbers in a food allergy 
immune response. WT, Bcl6FC, Blimp1FC and DKO mice were orally immunized 
twice with peanut protein + cholera toxin (PCT). 4 weeks after the last PCT 
immunization (day 36), spleens (SP) were analyzed for the indicated cell 
populations by flow cytometry. Representative contour dot plots for each cell 
staining are shown along with graphs showing average % of cells as a fraction of 
parental cell population and total yield of cells.  (A) Analysis of CD4+FOXP3+PD-
1+CXCR5+ TFR cells. Average TFR cells per group are quantitated as a 
percentage of FOXP3+CD4+ T cells, and absolute number. (B) Analysis of 
CD4+FOXP3- PD-1+CXCR5+ TFH cells. Average TFH cells are quantitated as a 
percentage of FOXP3- CD4+ T cells, and absolute number. (C) Analysis of 
B220+CD38- GL7+ GCB cells. Average GCB cells per group graphed as a 
percentage of B220+ cells and as absolute number. (D-E) Ratio of GC B cells to 
TFH cells from data in (A-C). (F) Titers of peanut-specific IgE by ELISA at day 36. 
P values were calculated by t test where * p < 0.05, ** p < 0.01, *** p < 0.0001. N 
= 4 - 6 mice; experiment was repeated twice with similar results. 
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Figure 33: Linear regressions between TFH and GCB cells (left plot), TFR and 
GCB cells (right plot) of Blimp1FC and DKO. 
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TFH cells from PCT-challenged WT, Bcl6FC, Blimp1FC and DKO mice (Fig. 34, 
Fig. 35). TFH gene expression was strongly affected by loss of TFR cells, leading 
to several hundred up-regulated and down-regulated DEGs for both Bcl6FC and 
DKO TFH cells, respectively (Fig 34A). Notably, Granzyme B (Gzmb) was strongly 
elevated in both Bcl6FC and DKO TFH cells (Fig 34A). Despite the large number 
of DEGs, the expression of key TFH genes remained intact (Fig. 34B). To better 
understand the nature of the DEGs in Bcl6FC and DKO TFH cells, we compared 
up-regulated DEGs from our dataset with published gene expression datasets. We 
found a highly significant enrichment of genes that were up-regulated in effector 
CD8 T cells and controlled by Stat4 in Th1 cells within the up-regulated DEGs from 
Bcl6 and DKO TFH cells (Fig. 34C, D). We then selected 23 genes up-regulated 
during CD8 effector T cell differentiation (Fig. 34E), which included genes for the 
cytotoxic proteins Gzmb and Perforin 1 (Prf1). About 75% of these 23 genes were 
dependent on Stat4 for expression and all 23 genes were robustly up-regulated in  
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Figure 34: TFR cells repress a cytotoxic gene program in TFH cells. 
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Figure 34: TFR cells repress a cytotoxic gene program in TFH cells. WT, Bcl6FC, 
Blimp1FC and DKO mice were orally immunized twice with PCT (N = 4). 4 weeks 
after the last immunization, TFH cells were purified from spleens by FACS. RNA 
was isolated from the TFH cells directly after sorting and subjected to RNAseq. (A) 
Volcano plots showing DEGs for Bcl6FC versus WT (155 genes up, 410 genes 
down) and DKO versus Blimp1FC (517 genes up, 1041 down). Blue are down-
regulated genes and purple are up-regulated genes, using FDR <0.05 and fold-
change >1.8 (linear). Gzmb is specifically marked in both plots. (B) Heat map 
showing expression of hallmark TFH genes assessed with RNAseq. Color scale 
shows log2 RPKM level of absolute expression of genes sorted alphabetically. (C-
D) Enrichment of DEGs in published datasets for genes associated with effector 
CD8 differentiation (GSE36168) (202) and Stat4 regulation in Th1 cells 
(GSE22105) (24), for Bcl6FC versus WT and DKO versus Blimp1FC comparisons, 
analyzing up-regulated DEGs and fraction of these genes within all expressed 
genes and probability (p values) for the enrichment. (C) pie charts showing unique 
and overlapping CD8 effector and Stat4 activated genes, (D) shows graphs of 
enrichment of only CD8 effector and Stat4 activated genes. (E-G) A set of 23 
hallmark genes was chosen for strong association with CD8 effector T cell 
differentiation, and used to create blue to yellow/red heat maps based on 
Log2RPKM gene expression for (E) naïve and effector CD8 T cells (GSE36168), 
(F) WT and Stat4-/- Th1 cells (GSE22105) and (G) TFH cells from WT, Bcl6FC, 
Blimp1FC and DKO mice. In (E-F), fold-change (FC) for the paired sets of genes 
is shown by a single column heat map.   
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Figure 35: MDS plot of TFH cells from RNAseq analysis. (Figure prepared by Dr. 
Jun Wan of IU). Bcl6FC, Blimp1FC and DKO mice were orally immunized twice 
with PCT (N = 4). 4 weeks after the last immunization, TFH cells were purified from 
spleens by FACS. RNA was isolated from the TFH cells directly after sorting and 
subjected to RNAseq.   
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Bcl6FC and DKO TFH cells compared to WT TFH cells (Fig. 34F, G). The 23 CD8 
cytotoxic effector genes were up-regulated to a much higher degree in DKO TFH 
cells than in Bcl6FC TFH, indicating a unique regulatory environment in those mice 
beyond loss of TFR cells. However, the expression of the 23 CD8 effector genes 
was nearly identical between WT and Blimp1FC TFH cells, also suggest 
augmented TFR cells in Blimp1FC do not affect TFH gene profile, showing that the 
highly up-regulated CD8 effector gene program in the DKO TFH cells was not 
simply due to loss of Blimp1 in Treg cells. Although the CD8 effector T cell gene 
profile seen in Bcl6FC and DKO TFH cells was significantly dependent on Stat4, 
these cells did not have a classical Th1 gene profile, as Ifng expression was not 
increased in these TFH cells and there was no clear Tbet (Tbx21) function (Fig. 
36A, B). Although we observed this CD8 effector T cell gene profile in TFR mutant 
mice, we wondered if this cytotoxic-like profile might appear in a virus infection 
system. We therefore used a published RNAseq dataset of TFH cells from SIV-
infected Macaques, and observed that there was a highly significant increase in 
expression of the 23 CD8 effector genes in SIV+ versus SIV- TFH cells (Fig. 36C). 
These data indicate that the aberrant TFH cell phenotype that develops in the 
absence of TFR cells can develop in a normal GC response after virus infection. 
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Figure 36: Expression of Th1 genes in TFH cells, Tbet regulation of cytotoxic 
genes, and cytotoxic TFH genes up-regulated after SIV infection.  (A) gene 
expression plots for Ifng, Tbx21 (Tbet) and Prdm1 (Blimp1) taken from the RNA-
seq data, where WT (red) TFH cells levels are set to 1 and fold changes are shown 
for Bcl6FC (blue), Blimp1FC (green) and DKO (magenta) TFH cells. Figure color 
codes correspond to Figure 32D. (B) Heat map of the gene set of 23 CD8 cytotoxic 
T cell genes described in Figure 34D-F, versus published gene expression data 
for WT and Tbet KO T cells (GSE105806). (C) Comparison of fold-changes in 
genes from TFH cells from SIV+ infected Macaques over uninfected TFH cells 
from un-infected Macaques (published RNA-seq data GSE69756). The 23 CD8 
cytotoxic T cell genes described in Figure 34D-F show a small but statistically 
significant increase in SIV+ TFH expressed genes over SIV- TFH expressed 
genes, compared to all other genes expressed in the TFH cells.  
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Figure 37: Cytotoxic gene expression in TFH cells and increased GCB apoptosis 
in TFR-deficient mice. WT, Bcl6FC, Blimp1FC and DKO mice were immunized 
with SRBC and spleens (SP) were analyzed for the indicated markers and cell 
populations by flow cytometry. (A-B) Analysis of CD4+FOXP3- PD-1+CXCR5+ 
TFH cells 9 days after immunization for either staining with (A) anti-granzyme B 
(Gzmb) or (B) anti-Eomesodermin (Eomes) Ab. Average Gzmb+ and Eomes+ TFH 
cells are quantitated and graphed as a percentage of TFH cells, and absolute 
number. N= 4; experiment was repeated 3 times. (C-D) Percent decrease in 
B220+CD38- GL7+ GC B cells 9 days after immunization in (C) Bcl6FC mice 
compared to WT mice, and (D) DKO mice compared to Blimp1FC mice. N= 8; 
experiment was repeated once. (E) Average Annexin V+ GC B cells in WT, 
Bcl6FC, Blimp1FC and DKO mice, 3 days after immunization. N= 4; experiment 
was repeated 3 times. 
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Cytotoxic gene expression in TFH cells and increased GCB apoptosis in 
TFR-deficient mice 
 We next set out to characterize Gzmb-expressing TFH cells and their 
potential role in killing GC B cells. Here we immunized with SRBCs, a model Ag 
that induces strong TFH responses. We stained TFH cells from WT, Bcl6FC, 
Blimp1FC and DKO mice for Granzyme B protein by flow cytometry, and saw a 
slight increase in Granzyme B in Bcl6FC TFH cells (Fig. 37A). However, we found 
a clearly distinct population of Granzyme B+ cells in the DKO TFH cells, consistent 
with the higher level of CD8 effector gene up-regulation in these cells (Fig. 37A). 
We next examined Eomesodermin (Eomes), a protein highly expressed in CD8 
effector T cells and cytotoxic CD4 T cells (203). DKO TFH cells had a clear 
population of Eomes+ TFH cells (Fig. 37B). We were also to detect a similar 
population of Klrg1+ DKO TFH cells that we could isolate by FACS to test gene 
expression (Fig. 38A). Klrg1+ DKO TFH cells had dramatically higher Gzmb mRNA 
and significantly lower expression of the TFH genes Bcl6, Il4 and Il21 (Fig. 38B). 
Thus, cytotoxic TFH cells may be less effective helper cells and may also actively 
kill GC B cells. Similar to our results with PCT immunization, we also observed 
very strong loss of GC B cell response in TFR-deficient mice after SRBC 
immunization (Fig. 37C, D). These data suggest that cytotoxic TFH cells might be 
able to kill GC B cells, leading to the loss of GC B cells we see in TFR-deficient 
mice. Although we were unable to demonstrate cytotoxic activity of TFH cells from 
DKO mice against GC B cells using in vitro assays, we could observe a 2-fold 
increase in apoptotic GC B cells in Bcl6FC and DKO mice (Fig. 37E).  Taken  
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Figure 38: Cytotoxic gene expression is enriched in Klrg1+ TFH cells. WT, Bcl6FC, 
Blimp1FC and DKO mice were immunized with SRBC and spleens were analyzed 
for Klrg1 on TFH cell populations by flow cytometry. (A) Analysis of CD4+FOXP3- 
PD-1+CXCR5+ TFH cells for Klrg1 expression 9 days after immunization. Average 
Klrg1+ TFH cells are quantitated and graphed as a percentage of TFH cells, and 
absolute number. N= 4; experiment was repeated 3 times. (B) DKO TFH cells were 
separated into Klrg1+ and Klrg1- populations by FACS, and RNA was prepared 
directly after sorting. RT-QPCR was used to analyze gene expression in Klrg1+ 
and Klrg1- TFH cells. Graphs show relative expression for the indicated genes with 
the mRNA level in Klrg1- cells set as 1. 
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together, our data define a new cytotoxic-like TFH cell subset regulated by TFR 
cells and likely by Stat4. Gzmb-expressing circulating TFH cells have been found 
in humans, and the development of this population is Stat3-dependent (204). We 
were unable to find an enrichment of Stat3 target genes in our TFH cell data, 
suggesting that there can be different origins of Gzmb-expressing TFH cells.  
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DISCUSSION 
T follicular helper cells 
TFH cells orchestrate the germinal center reaction and the production of 
high affinity Abs to Ag, yet the pathways for how TFH cells develop are not well 
understood, either in vivo or in vitro. We have uncovered a completely novel mode 
of inducing the master TFH cell regulator Bcl6, which involves the metabolic sensor 
AMPK. We also analyzed the critical interplay between two transcription factors 
that control TFH cell development in opposing pathways: Bcl6 and Blimp1.  
 
Our work ties into extensive recent work showing effector T cell responses 
are promoted by glycolysis and AMPK (96, 185, 186, 205), however TFH cell 
responses were not analyzed in these previously published studies. Our findings 
add a new twist to metabolic regulation of T cells, and indicate that inhibition of 
glycolysis, with resulting activation of AMPK, induces Bcl6 expression, which can 
promote TFH cell responses. Although previous studies have shown that Bcl6 is 
positively regulated by AMPK in endothelial cells (191), and that Bcl6 is up-
regulated by glucose deprivation (GD) in pancreatic cancer cells (171), our data 
here shows that this pathway is operational in CD4 T cells, both in mice and 
humans, and that this pathway can impact TFH cell differentiation. 
 
Curiously, TFH cells have a unique metabolic profile, with a dampened 
metabolism compared to other effector T cells (170). This dampened metabolism 
may be explained in part because Bcl6 is able to repress genes in the glycolysis 
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pathway (172). Thus, if Bcl6 suppresses glycolysis, this can contribute to the 
decreased glycolysis in TFH cells. An unresolved question is how this dampened 
metabolism contributes to the function of TFH cells. In the GC, B cells present 
cognate Ag to TFH cells and stimulate the TFH cells through the TCR to allow for 
elaboration of helper cytokines. TFH cells need to be specifically activated in order 
to help GC B cells, and it has been proposed that strict control of cytokine secretion 
by TFH cells is a key aspect of their function (109, 206). How cytokine expression 
is controlled in TFH cells following interaction with GC B cells presenting cognate 
Ag is a particularly important question for understanding B cell selection in the GC. 
We propose that metabolism is normally dampened in TFH cells specifically to limit 
the non-specific secretion of cytokines by TFH cells in the GC, and that metabolism 
is dramatically activated in TFH cells that are stimulated by cognate GC B cells. 
 
Previous studies have found that Bcl6 is induced by AMPK in endothelial 
cells (191), and that Bcl6 is up-regulated following glucose deprivation (GD) in 
pancreatic cancer cells (171), these studies presented different mechanisms for 
how Bcl6 is induced. In the endothelial cell study, AMPK was shown to inactivate 
PARP1, which normally represses BCL6 (191), and thus AMPK signaling relieves 
repression on BCL6. In the GD study, activated Foxo1 was shown to induce Bcl6 
expression (171). Our laboratory showed many years ago that Foxo4 positively 
regulates Bcl6 (207), and AMPK can regulate multiple Foxo factors (208). 
Interestingly, Foxo1 was shown to repress early TFH cell differentiation, but also 
was required for maximal Bcl6 expression and full TFH cell differentiation (209). 
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Overall, it is likely that the regulatory pathway for how AMPK activates BCL6 is 
complex and involves several factors, but a common theme is factors that respond 
to metabolic signals. Apart from activation by AMPK, PARP-1 utilizes the metabolic 
product NAD+ for its enzymatic function, and is thus responsive to the metabolic 
state of the cell (210). 
 
Although we found Bcl6 was strongly induced when glycolysis was inhibited, 
inhibition of glycolysis is also detrimental to T cell activation and proliferation (96, 
185, 186, 205). Thus, during a strong T cell proliferative response, abundant 
glucose is required, and it is unlikely that Bcl6 will be activated by AMPK signaling. 
We hypothesize that during a strong T cell response, glucose can get depleted 
locally, and this may lead to Bcl6 activation via AMPK. Indeed, we showed that 
Bcl6 was induced by GD following initial T cell activation in the presence of 
glucose.  Although speculative, this is a plausible pathway for the development of 
TFH cells during an active immune response, and importantly it is a way for TFH 
cells to develop in the presence of inhibitory IL-2.  
 
The fact that Bcl6 represses glycolysis (172) makes the activation of Bcl6 
transcription by GD, where glycolysis is inhibited, remarkable. This connection 
indicates that Bcl6 may be part of a feedback loop used by the cell to shut off 
glycolysis, when glucose is in short supply. This potential regulatory circuit is novel 
and a subject of future research. Whether induction of Bcl6 by AMPK has different 
effects on glycolysis in GD conditions versus when glucose is present is another 
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important issue for future investigation.  Ultimately, these findings have therapeutic 
potential, since targeting AMPK by pharmaceutical agents can be used for 
augmenting TFH cells during vaccination, or for inhibiting TFH cells in an auto-
immune disease setting. 
 
To better understand the pathways for how TFH cells develop, we analyzed 
the critical interplay between two transcription factors that control TFH cell 
development in opposing pathways: Bcl6 and Blimp1. Despite the recent 
characterization of Bcl6 target genes in CD4 T cells (101, 102), the key 
mechanisms by which Bcl6 promotes TFH cell differentiation are not well 
understood. A frequently cited pathway proposed for Bcl6-mediated control of TFH 
cell differentiation is that Bcl6 inhibits terminal CD4 T cell differentiation by 
repressing the Prdm1 (Blimp1) transcription (51, 70, 82, 87, 97). Blimp1 is a potent 
inhibitor of TFH cell differentiation, but the mechanism by which Blimp1 represses 
TFH cell differentiation has not been clarified. Using mice doubly deficient in both 
Bcl6 and Blimp1, we demonstrate that Blimp1 does not repress TFH cell 
differentiation in the absence of Bcl6 function. This data indicates that the major 
role of Blimp1 in inhibiting TFH cell differentiation is by repressing Bcl6 expression, 
and this finding clarifies an important aspect of the transcriptional control of TFH 
cell differentiation. 
 
We also investigated the role of Bcl6 and Blimp1 in controlling TFR cell 
differentiation. The signaling pathways that control TFR cell differentiation are 
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poorly understood, but experimental evidence indicates that TFR cells differentiate 
from both Foxp3+ regulatory T cells that up-regulate Bcl6 as they become TFR 
cells (106, 211), and also from Foxp3- naive CD4 T cells that up-regulate both Bcl6 
and Foxp3 (54). TFR cells require Foxp3, Bcl6 and Stat3 function for their 
development (50, 106, 109, 110, 211), but other genes that critically control their 
development have not been well characterized. Here we show that Blimp1 can 
repress TFR cell differentiation by a Bcl6-independent pathway. One mechanism 
for this effect may relate to regulation of NFATc1/NFAT2, which has been shown 
to be important for up-regulation of CXCR5 on TFR cells as well as for expression 
of PD-1 (105, 118). Blimp1 has been shown to repress NFATc1/NFAT2 expression 
(105), and thus Blimp1 should have a suppressive role for CXCR5 and PD-1, both 
of which are key genes increased in TFR cells. Increased expression of 
NFATc1/NFAT2 in Blimp1-deficient regulatory T cells could lead to Bcl6-
independent expression of CXCR5 and PD-1, and appearance of TFR–like cells.  
Whether the TFR–like cells that develop in dcKO mice are true functional TFR cells 
is difficult to determine since TFH cells and GCB cells do not develop.  We expect 
that Blimp1-deficient Foxp3+ regulatory T cells with increased CXCR5 and PD-1 
would have suppressive function and have access to the B cell follicle. However, 
these cells may have altered expression of suppressive cytokines, survival and 
kinetics in the absence of Bcl6. Notably, Blimp1 promotes expression of the 
important suppressive cytokine IL-10 (192, 212), and thus Blimp1-deficient TFR–
like cells likely have decreased IL-10 and may have altered suppressive activity. 
However, the role of IL-10 in TFR cells is not yet established, and this question 
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cannot yet be answered definitively. Since TFR–like cells develop in dcKO mice, 
we cannot completely rule out that TFH cells also develop in dcKO mice but that 
the TFR–like cells suppress the growth of this population and keep them at an 
insignificant level. One argument against this idea is our previous work showing 
that TFR cells do not actually limit the size of the TFH cell population (109, 110).  
 
Our data revealed a new insight into IL-10 regulation, since we showed here 
that Bcl6 represses transcription of Il10 independently of Blimp1 in primary CD4 T 
cells. Since Blimp1 has been shown to promote IL-10 expression (192, 212), one 
possibility was that Bcl6 represses Il10 transcription indirectly by repressing Prdm1 
(Blimp1) transcription. Thus our data rules out a mechanism of IL-10 control where 
Bcl6 acts on IL-10 by repressing Blimp1 and causing decreased Il10 transcription, 
and shows that Bcl6 is a direct repressor of Il10 expression. Indeed, Bcl6 has been 
shown to bind to a distal enhancer region for both mouse and human Il10 genes 
(88, 213), but it has not been clear if this binding leads to functional repression by 
Bcl6. Our data support the idea that this is a key regulatory region for Bcl6-
mediated repression of Il10. 
 
Bcl6 has been shown to promote PD-1 expression previously (104), but the 
mechanism for this regulation has not been defined. This pathway is unusual since 
Bcl6 is primarily, if not exclusively, a transcriptional repressor protein, and there 
has long been a question about how Bcl6 can activate genes that are induced at 
high levels in TFH cells such as PD-1 and CXCR5.  One early explanation was 
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that microRNAs that suppress TFH cell markers are themselves targets of Bcl6, 
and thus Bcl6 induces TFH cell gene expression by silencing these suppressive 
microRNAs (193). However, this microRNA pathway has not been supported by 
subsequent research and more recently microRNAs thought to be suppressed by 
Bcl6 were shown to be important for TFH cell development (214, 215). We tested 
the role of microRNAs in induction of PD-1 and CXCR5 by Bcl6 using our RV 
system, and found that Bcl6 could promote PD-1 and CXCR5 in Dicer cKO T cells, 
which are unable to generate microRNAs. In the present study, we identified a 
novel Tbet-dependent pathway for the induction of PD-1 by Bcl6. Tbet is a 
transcriptional repressor of PD-1 gene expression (194), and Bcl6 is a potent 
negative regulator of Tbet (195). We therefore demonstrated that Bcl6 could 
counter-repress the negative regulation of PD-1 by Tbet. The unexpected finding 
was that even though Blimp1 is a potent negative repressor of PD-1, Bcl6-
mediated positive regulation of PD-1 acts independently of Bcl6 repressing Blimp1. 
In summary, we have clarified several aspects of Bcl6 control over TFH cell and 
TFR cell differentiation. Specifically, we have found that Blimp1 primarily represses 
TFH cell differentiation through a Bcl6-dependent pathway, Blimp1 represses TFR 
cell differentiation through both Bcl6-dependent and Bcl6-independent pathways 
and Bcl6 can promote PD-1 expression by a novel Blimp1-independent 
mechanism involving Tbet inhibition. 
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T follicular regulatory cells 
T follicular regulatory cells help control the Germinal Center (GC) and Ab 
response and the function of TFR cells in the GC is not well understood, however 
the dominant paradigm in the TFR field has been that TFR cells repress excessive 
TFH and GC B cell proliferation and help promote stringent selection of high affinity 
B cells. Newer mouse models have allowed the study of TFR cell function with 
more precision than previous approaches. Here we show for the first time that Ag-
specific IgE responses induced in a food allergy challenge system are uniquely 
dependent on TFR cells and that TFR cells play an active helper role in the 
production of IgE. Our data also point to a key role of IL-10 made by TFR cells in 
promoting the development of IgE secreting cells from the GC. The data presented 
here fit into an emerging helper model of TFR cell function that reshapes the 
standard view of TFR cells. 
 
The first studies of TFR cells described them as suppressors of the GC and 
Ab response (49, 50, 106), and most studies on TFR cells have operated within 
this conceptual framework of TFR cells as suppressors (111, 216). Recently 
however, a different model has emerged-- that TFR cells act as helper cells within 
the GC to facilitate GCB cell maintenance and Ag-specific Ab production. Laidlaw 
et al showed a key helper function for TFR cells in the GC was producing IL-10 
that helped promote GCB cell entry into the dark zone and maintaining the size of 
the GC (68). Laidlaw et al studied TFR function after Lymphocytic Chorio-
Meningitis Virus (LCMV) infection (68), a very different type of immune response 
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than the food allergy model studied here. While Laidlaw et al observed significant 
decreases in GC size from loss of TFR cell-derived IL-10, comparable to what we 
observed in our study here, the effects on virus-specific IgG were modest (68). Our 
earlier work with TFR-deficient mice also showed a relatively small loss of Ag-
specific IgG using model Ags such as Sheep Red Blood Cells (110). In the original 
studies that reported TFR cells, mixed bone marrow methods were used to look at 
the functions of TFR cells (49, 50). A few other studies also used in vitro co-culture 
system to study TFR cells which showed some interesting findings (149, 217). In 
our lab, a TFR-deficient mouse model where the Bcl6 gene is specifically deleted 
in Foxp3+ T cells (Bcl6-flox/flox Foxp3-Cre or Bcl6FC mice) has been used by us 
and others to study TFR cell function in immune and autoimmune responses. We 
think this Bcl6FC mouse model is a more accurate tool for the study TFR cells 
though knockout Bcl6 gene in Tregs may have some other unexpected cell intrinsic 
effects. Here we show a complete loss of Ag-specific IgE in the absence of TFR 
cells, indicating that there is a particularly critical role of TFR cells to act as helpers 
in the allergic IgE response. Our data also show that blockade of IL-10 signaling 
on B cells mimics the effect of loss of TFR cells specifically on Ag-specific IgE, 
indicating that TFR cell-derived IL-10 is likely to mediate the positive effect of TFR 
cells in this response. 
 
One major question from our data is therefore why GC-dependent IgE 
responses appear to be much more sensitive to the loss of TFR cells than GC-
dependent IgG responses. The answer is likely to lie with the unique nature of IgE 
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as an Ag receptor for B cells in the GC. Specifically, IgE+ switched GC B cells 
have altered Ag receptor signaling, are unstable and display increased apoptosis, 
and selection of IgE+ B cells in the GC is less efficient than with B cells expressing 
other Ig isotypes (218-222). Interestingly, inhibition of apoptosis in the GC helps to 
promote IgE responses (223). A previous study showed that IgE+ GC B cells have 
little to do with generating the high-affinity memory IgE response (224). Recently, 
both mouse and human studies showed that high-affinity IgE producing plasma B 
cells are generated from IgG-memory B cells upon re-exposure to Ag through 
additional class-switch recombination to IgE (225, 226). The precursors of IgE+ 
plasmablasts appear to be IgG1+ memory B cells in mice and IgG4+ memory B 
cells in humans (225, 226). These IgG+ memory B cells come from a switch from 
IgM to IgG and are thought to be generated in the GC (225-227). We have found 
that IgG1+ GC B cells were significantly decreased in our Bcl6FC mice after PCT 
challenge on D36 compared with WT (data not shown). It is highly possible that 
TFR cells positively promote the switch of IgG1+ memory B cells into high-affinity 
IgE producing plasmablasts, though more work is needed to address this. 
Similarly, IL-10 may play a fundamental role in the regulation of this IgE switching 
and it may directly affect the generation of IgG1+ memory B cells within the GC for 
we showed decreased GC B cells in MB1-Il10ra-/- mice. We propose that IL-10 
made by TFR cells helps to stabilize GC B cells and promotes the generation of 
stable high-affinity IgE-secreting plasmablasts. Thus, for allergic diseases 
mediated by IgE, TFR cells represent an important new target of control over IgE 
production. 
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Our data have significant implications for food allergy responses and other 
IgE-mediated allergic diseases. Since IgE is a central mediator of allergic disease, 
much research has gone into developing inhibitors of IgE and IgE-induced 
responses (228-231). Our data shows that blocking IL-10 signaling after the 
initiation of the peanut allergy challenge can potently inhibit the production of 
peanut-specific IgE. This suggests that IL-10 is a new mediator of IgE responses 
and may be exploited to inhibit IgE-mediated allergy. IL-10 is a multi-functional 
cytokine with both positive and negative regulatory function and is classically 
considered a key suppressive cytokine. Recent results suggest that IL-10 
produced by TFR cells is also a major positive factor for Ab responses that may 
be a good target for inhibition in the right type of allergic disease, such as food 
allergy.  
 
IL-10 is becoming more widely seen as a positive factor in GCB cell 
responses (68, 139, 232), but our study is the first to show the regulation of IgE+ 
GCB cell responses by IL-10. More research is required to determine whether IL-
10 non-specifically promotes the survival of IgE+ GC B cell responses after the 
switching stage or whether IL-10 might specifically increase the early induction of 
IgE switching. Additionally, more studies are needed to understand if TFR cells 
can act both as suppressors and helpers depending on the exact type of immune 
response, or if TFR cells default towards a helper role for immune responses to 
non-self Ags (216). Despite these questions, our work has opened a new 
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understanding of the regulation of IgE responses as well as helped us recognize 
the complex function of TFR cells in the GC. 
 
Our data in the study of cytotoxic TFH cells define a new cytotoxic-like TFH 
cell subset that is repressed by TFR cells and is promoted by pro-inflammatory 
signals (e.g. virus infection or Treg cell defects). These Gzmb-expressing TFH 
cells have the potential to kill B cells in the GC. Our findings therefore reveal a new 
regulatory pathway for the GC and high-affinity Ab production. 
 
TFR cells have been generally considered to repress the GC and Ab 
response (111, 216, 233, 234). Our data here show a very clear and potent helper 
effect of TFR cells in the GC, in two different types of immune challenge (PCT and 
SRBC). Thus our data is more consistent with a recent study that showed that TFR 
cells can help promote the Ag-specific IgG and GC response by expressing IL-10 
(68). However, our data reveal a new pathway for TFR cells to help the GC 
response, by inhibiting the development of cytotoxic-like TFH cells. 
 
Our data indicate that the aberrant TFH cell phenotype that develops in the 
absence of TFR cells can also develop in a TFR cell sufficient GC response after 
virus infection (Fig. 36C). Gzmb-expressing circulating TFH cells have been found 
in humans, and the development of this population is Stat3-dependent (204). 
However, we were unable to find an enrichment of Stat3 target genes in our TFH 
cell data (not shown), suggesting there may be different origins for these circulating 
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Gzmb-expressing TFH cells. We saw a strong correlation of TFH cytotoxic genes 
with Stat4 regulation. This may indicate that IL-12 is increased in the GC 
environment in the absence of TFR cells. A key function of Tregs is to down-
modulate DC function, including the secretion of cytokines such as IL-12 (235, 
236). A similar suppression of cytokine secretion by DCs, may also be a mode of 
TFR cell function in the GC or in the surrounding lymphoid environment.  
 
Very recently, Gzmb-expressing TFH cells with a genotype related to our 
cytotoxic TFH cells have been found in GCs in human tonsillitis (237). How these 
human cytotoxic TFH cells develop is not clear but they appear to be a defective 
or exhausted state of TFH cell differentiation induced by chronic infection (237). It 
is tempting to speculate that defective TFR function leads to these human Gzmb-
expressing TFH cells, but more research is required for this question. However, 
our results do show the conservation of this cytotoxic TFH cell pathway in humans. 
 
Overall, our findings raise the possibility that cytotoxic TFH cells are a 
normal part of the GC response and that Gzmb+ TFH cells kill GC B cells and help 
to fine-tune the Ab response. Furthermore, cytotoxic TFH cells may also play a 
role in controlling virus infection in the GC. Thus, increased development of these 
aberrant TFH cells may be beneficial after virus infection. The precise function of 
TFR cells in suppressing Gzmb-expressing TFH cells will be an important area for 
future research. 
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FUTURE DIRECTIONS 
Here we documented that Bcl6 is strongly induced when glycolysis is 
inhibited, the fact that Bcl6 represses glycolysis (172) makes the activation of Bcl6 
transcription by GD, where glycolysis is inhibited, remarkable. This connection 
indicates that Bcl6 may be part of an important feedback loop used by the cell to 
shut off glycolysis, when glucose is in short supply. This potential regulatory circuit 
is very novel and a subject of future research. Whether induction of Bcl6 by AMPK 
has different effects on glycolysis in GD conditions versus when glucose is present 
is another important issue for future investigation.  These findings have therapeutic 
potential, since targeting AMPK by pharmaceutical agents can be used for 
augmenting TFH cells during vaccination, or for inhibiting TFH cells in an auto-
immune disease setting. 
 
Many transcription factors may be involved in the induction of Bcl6 
expression by GD such as the deacteylase Sirtuin-1 (Sirt1) which can be activated 
by AMPK (238, 239). We could use primary mouse naïve CD4+ T cells in 
secondary stimulation cultures and test compounds such as EX527, the highly 
specific inhibitor for Sirt1 (84, 239). Additionally, Bcl6 self-repression is uniquely 
dependent upon the co-repressor protein CTBP, loss of CTBP binding, may also 
converge on the Bcl6 promoter to increase transcription. The binding of Bcl6 and 
CTBP factors to the Bcl6 promoter and other regulatory regions of the Bcl6 gene 
has already been established in multiple studies (84). We may use EL4 cells for 
Chromatin immunoprecipitation (CHIP) assays initially, with Abs to each of these 
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factors. Bcl6 and CTBP are expected to be bound at a higher rate to the Bcl6 gene 
in +glucose conditions. We may also use the inhibitor MTOB (4-methylthio-2-
oxobutanoate) in our study to look at Bcl6 expression under different conditions 
(240).  
 
Though TFH cells have been studied extensively, TFR cells have only been 
analyzed in a very small fraction of infectious disease models and immunological 
diseases such as allergy and autoimmunity. Testing TFR cell function in various 
disease states will be an important area for future research on TFR cells. Also 
unknown is if TFR cells affect diseases that are not driven by Ab-mediated 
pathology. Whether TFR cells play a regulatory role in cancer, diabetes, heart 
disease, atherosclerosis, or other types of inflammatory diseases, is open for 
exploration. The mechanism of TFR cell help in the GC is not completely 
understood and an important topic is why some types of GC responses seem to 
rely on TFR cells for help whereas other GC responses are only mildly affected or 
not affected at all by loss of TFR cells. A major question for future studies is 
whether TFR cells switch between help and suppression in the GC for foreign Ag, 
or primarily act as helpers for foreign Ag and suppressors of autoimmune 
responses. If TFR cells act as suppressor cells of non-autoimmune responses in 
the GC, what mechanism of suppression do they use, and what controls whether 
TFR cells act as suppressors versus helpers? Do human and mouse TFR cells 
have similar helper and repressor functions? TFR-like cells have been found 
circulating in both mice and humans; what is the relationship of these cells to TFR 
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cells in the GC? Also unclear is how TFR cells regulate Ab affinity maturation and 
TFH responses. A major question is whether TFR cells regulate the generation or 
differentiation or survival of memory B cells. Lastly, almost nothing is known about 
what signals drive TFR cell responses to the GC and what Ags do they recognize? 
Thus, there are huge numbers of vital questions about TFR cells that need to be 
answered through more research.  
 
In our food allergy model, we still don’t know if TFR cells directly affect IgE+ 
plasmablast cell differentiation. An effect of increased survival or proliferation on 
IgE+ GC B cells may be difficult to detect if these cells differentiate rapidly into 
IgE+ plasmablasts and plasma cells. Nonetheless, further study is needed to 
analyze GCB cell and plasma cell responses. We could use flow cytometry to 
assess GC B cells that have switched to IgG1 or IgE at each time-point in each 
mouse model. This part of data would provide some preliminary information 
regarding IgE+ Ab producing cell regulation. PtenFC mice may be used as a 
positive model here for this study purpose. Little is known how IL-10 regulates IgE 
responses, an obvious question is does IL-10 promote IgE+ GCB proliferation or 
promote Ab isotype switching to IgG1 then IgE? Il10ra cKO mice which have defect 
of IL-10 signaling in B cells may be used with IgE reporter mice to track IgE+ B cell 
development.  
 
For the cytotoxic TFH cell pathway, more functional studies of these TFH 
cells need to be carried out. Either Gzmb inhibitor or Gzmb gene deficiency may 
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be applied to our DKO mice to test the function of TFH cell cytotoxicity. Is there 
any change of GCB cells when Gzmb is knocked out in T cells? It will also be 
interesting to see if humoral Ab responses are affected by Gzmb inhibition or not. 
In our data presented above we showed that cytotoxic TFH cells seem to be 
STAT4 dependent, we have some preliminary data showing that Il12a expression 
is highly upregulated in DCs of DKO mice (data not shown), but how this 
upregulated IL-12/STAT4 signaling impacts TFH phenotype remains unknown. In 
vivo blocking of IL-12 of DKO mice using blocking Ab may partially address if IL-
12 is fundamental for the development of cytotoxic TFH cells.  
 
Even though Tregs act overwhelmingly as major suppressors of the immune 
response, TFR cells provide a striking and clear example of Treg cells acting as 
“helper” cells for the immune response. At least part of this TFR cell helper function 
is producing IL-10 that promotes GC B cell growth and the GC-dependent high 
affinity Ab response. Thus, in the context of the GC response, TFR cells appear to 
maintain a key balance between help (GC maintenance, Ab response, Ab affinity) 
and suppression (TFH cell numbers, GC B cell numbers, TFH cell cytokines, auto-
Abs). One interesting idea is that the auto-reactivity and suppressive capability of 
Treg is used to help control auto-immunity in the GC but has been co-opted to also 
promote the overall GC response. Additional future work is needed to fully 
understand the role of TFR cells in the overall humoral immune response, and in 
the larger scope of the immune system. 
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